sampleID;cohort;histological_type;expression_subtype_LUAD;expression_subtype_LUSC;PANCAN_Cluster_Cluster_PANCAN;PANCAN_DNAMethyl_PANCAN;PANCAN_UNC_RNAseq_PANCAN_K16;pathologic_M;pathologic_T;pathologic_N;pathologic_stage;age;gender;overall_survival;overall_survival_months;days_to_death;days_to_last_followup;disease_status;disease_free_months;smoking_history;pack_per_year
TCGA-05-4244;NA;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;;;;;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
TCGA-05-4249;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;67;MALE;Alive;50.03;NA;1158;DiseaseFree;50.03;3;52
TCGA-05-4250;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N1;stage III;79;FEMALE;Dead;3.98;121;NA;NA;NA;4;47
TCGA-05-4382;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;68;MALE;Alive;19.94;NA;607;Recurred/Progressed;10.97;4;62
TCGA-05-4384;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;66;MALE;Alive;13.99;NA;426;Recurred/Progressed;6.01;3;20
TCGA-05-4389;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;70;MALE;Alive;44.97;NA;1369;DiseaseFree;44.97;3;43
TCGA-05-4390;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;58;FEMALE;Alive;36.99;NA;1126;Recurred/Progressed;12.98;4;15
TCGA-05-4395;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T4;N2;stage III;76;MALE;Dead;0;0;NA;NA;NA;3;NA
TCGA-05-4396;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T4;N1;stage III;76;MALE;Dead;9.95;303;NA;NA;NA;3;19
TCGA-05-4397;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;65;MALE;Dead;24.01;731;NA;NA;NA;2;45
TCGA-05-4398;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T4;N3;stage III;47;FEMALE;Alive;47.01;NA;1431;DiseaseFree;47.01;2;72
TCGA-05-4402;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M1;T2;NX;stage IV;57;FEMALE;Dead;8.02;244;NA;NA;NA;1;NA
TCGA-05-4403;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;76;MALE;Alive;18.99;NA;578;DiseaseFree;18.99;3;NA
TCGA-05-4405;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;74;FEMALE;Alive;20.04;NA;610;DiseaseFree;20.04;4;65
TCGA-05-4410;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;62;MALE;Alive;0;NA;0;DiseaseFree;0;4;98
TCGA-05-4415;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T4;N2;stage III;57;MALE;Dead;2.99;91;NA;Recurred/Progressed;1.97;4;29
TCGA-05-4417;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;51;FEMALE;Alive;14.95;NA;455;DiseaseFree;14.95;4;56
TCGA-05-4418;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N2;stage III;69;MALE;Dead;9;274;NA;NA;NA;2;25
TCGA-05-4420;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;41;MALE;Alive;29.96;NA;912;DiseaseFree;29.96;2;38
TCGA-05-4422;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T2;N0;stage I;68;MALE;Alive;11.99;NA;365;DiseaseFree;11.99;4;147
TCGA-05-4424;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T3;N0;stage II;70;MALE;Alive;29.99;NA;913;Recurred/Progressed;5.03;4;50
TCGA-05-4425;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T2;N0;stage IV;70;FEMALE;Alive;21.98;NA;669;DiseaseFree;21.98;3;28
TCGA-05-4426;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;71;MALE;Alive;25.99;NA;791;Recurred/Progressed;15.01;3;20
TCGA-05-4427;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;65;FEMALE;Alive;25.99;NA;791;DiseaseFree;25.99;4;8
TCGA-05-4430;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;59;FEMALE;Alive;25;NA;761;DiseaseFree;25;4;80
TCGA-05-4432;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T2;N1;stage II;66;MALE;Alive;25;NA;761;DiseaseFree;25;2;58
TCGA-05-4433;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;82;MALE;Alive;23.98;NA;730;DiseaseFree;23.98;3;1
TCGA-05-4434;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T4;N1;stage IV;67;FEMALE;Dead;15.01;457;NA;NA;NA;2;15
TCGA-05-5420;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;67;MALE;Alive;15.01;NA;31;Recurred/Progressed;8.05;4;40
TCGA-05-5423;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;65;MALE;Alive;4.96;NA;151;DiseaseFree;4.96;3;72
TCGA-05-5425;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;68;MALE;Alive;28.98;NA;90;Recurred/Progressed;15.97;3;40
TCGA-05-5428;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N1;stage II;57;MALE;Alive;22.01;NA;0;DiseaseFree;22.01;3;30
TCGA-05-5429;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N2;stage III;60;MALE;Dead;9.03;NA;30;NA;NA;1;NA
TCGA-05-5715;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;69;FEMALE;Alive;2.04;NA;62;DiseaseFree;2.04;1;NA
TCGA-18-3406;NA;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;;;;;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
TCGA-18-3407;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T2;N0;stage I;72;MALE;Dead;4.47;136;NA;NA;NA;3;40
TCGA-18-3408;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;77;FEMALE;Dead;75.69;NA;2099;Recurred/Progressed;58.9;4;30
TCGA-18-3409;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;74;MALE;Alive;123.09;NA;2417;Recurred/Progressed;75.26;3;20
TCGA-18-3410;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N0;stage II;81;MALE;Dead;4.8;146;NA;NA;NA;3;NA
TCGA-18-3411;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N2;stage III;63;FEMALE;Alive;117.48;NA;1415;DiseaseFree;117.48;2;50
TCGA-18-3412;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;52;MALE;Dead;11.33;345;NA;Recurred/Progressed;8.97;4;25
TCGA-18-3414;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M1;T4;N1;stage IV;73;MALE;Dead;23.52;716;NA;NA;NA;4;25
TCGA-18-3415;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;77;MALE;Dead;92.08;NA;1810;NA;NA;3;30
TCGA-18-3416;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T2;N1;stage II;83;MALE;Dead;31.96;NA;956;Recurred/Progressed;30.88;3;40
TCGA-18-3417;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M1;T2;N1;stage IV;65;MALE;Dead;36.04;NA;758;NA;NA;3;25
TCGA-18-3419;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;73;MALE;Alive;92.35;NA;53;DiseaseFree;92.35;4;50
TCGA-18-3421;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T2;N0;stage I;65;MALE;Alive;86.89;NA;1331;DiseaseFree;86.89;4;40
TCGA-18-4083;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;63;MALE;Dead;6.18;188;NA;NA;NA;2;45
TCGA-18-4086;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;64;MALE;Dead;2.79;85;NA;NA;NA;4;30
TCGA-18-4721;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;74;MALE;Alive;154.2;NA;2754;DiseaseFree;154.2;4;NA
TCGA-18-5592;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N0;stage II;57;MALE;Alive;49.9;NA;92;DiseaseFree;49.9;3;40
TCGA-18-5595;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T2;N0;stage I;50;MALE;Dead;27.17;827;NA;NA;NA;1;NA
TCGA-21-1070;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T3;N0;stage III;60;FEMALE;Alive;119.45;NA;3516;DiseaseFree;119.45;4;15
TCGA-21-1071;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;67;MALE;Dead;46.85;1426;1426;Recurred/Progressed;32.62;2;90
TCGA-21-1072;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;BRCA CIMP c7;squamous-like c4;M0;T2;N0;stage I;75;MALE;Alive;99.08;NA;3016;DiseaseFree;99.08;3;NA
TCGA-21-1075;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;57;MALE;Alive;70.11;NA;2134;DiseaseFree;70.11;2;74
TCGA-21-1076;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;54;FEMALE;Alive;60.84;NA;1852;Recurred/Progressed;51.74;4;35
TCGA-21-1077;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;64;MALE;Dead;34.76;1058;1058;Recurred/Progressed;21.16;4;56
TCGA-21-1078;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C8-BLCA;Cluster 5;BLCA nonsquamous-like c1;M0;T2;N0;stage I;77;MALE;Dead;15.57;474;474;Recurred/Progressed;8.44;4;9
TCGA-21-1079;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T3;N0;stage III;71;MALE;Dead;31.7;965;965;Recurred/Progressed;10.41;3;80
TCGA-21-1080;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;66;MALE;Alive;122.34;NA;3724;DiseaseFree;122.34;4;100
TCGA-21-1081;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;69;MALE;Dead;9.33;284;284;NA;NA;4;45
TCGA-21-1082;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;61;MALE;Alive;119.71;NA;3644;DiseaseFree;119.71;NA;NA
TCGA-21-1083;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;OV-like c1;RNA cluster 12;M0;T1;N0;stage I;75;MALE;Dead;43.2;1315;267;NA;NA;2;240
TCGA-21-5782;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;68;FEMALE;Dead;31.6;962;962;NA;NA;4;48
TCGA-21-5783;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;squamous-like c4;M0;T2;N0;stage I;76;MALE;Dead;88.04;2680;NA;NA;NA;3;NA
TCGA-21-5784;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;80;FEMALE;Alive;41.66;NA;908;DiseaseFree;41.66;3;14
TCGA-21-5786;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;64;MALE;Alive;33.9;NA;661;Recurred/Progressed;26.84;2;75
TCGA-21-5787;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;65;MALE;Dead;10.81;329;329;Recurred/Progressed;3.38;4;100
TCGA-21-A5DI;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;77;MALE;Alive;32.16;NA;979;DiseaseFree;32.16;3;NA
TCGA-22-0940;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N1;stage II;71;MALE;Dead;21.98;669;608;NA;NA;3;25
TCGA-22-0944;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;61;MALE;Dead;7.33;223;223;NA;NA;2;38
TCGA-22-1000;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;M0;T2;N0;stage I;76;MALE;Dead;14.91;454;NA;Recurred/Progressed;8.64;4;40
TCGA-22-1002;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;69;MALE;Dead;4.3;131;131;NA;NA;4;85
TCGA-22-1005;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;M0;T1;N0;stage I;63;MALE;Dead;64.16;1953;1953;NA;NA;4;40
TCGA-22-1011;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N0;stage I;73;MALE;Dead;1.74;53;53;NA;NA;2;83
TCGA-22-1012;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;80;FEMALE;Dead;14.09;429;NA;NA;NA;4;60
TCGA-22-1016;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;65;MALE;Dead;27;822;822;NA;NA;3;40
TCGA-22-1017;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;62;MALE;Dead;48.78;1485;NA;Recurred/Progressed;29.7;4;NA
TCGA-22-4591;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N2;stage III;80;MALE;Dead;20.47;623;623;Recurred/Progressed;14.55;2;NA
TCGA-22-4593;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage II;77;MALE;Dead;35.05;1067;1067;NA;NA;4;30
TCGA-22-4594;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T3;N2;stage III;60;FEMALE;Dead;48.29;1470;1470;NA;NA;4;40
TCGA-22-4595;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;;T3;N2;stage III;57;MALE;Dead;24.11;734;734;Recurred/Progressed;19.19;2;37
TCGA-22-4596;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;69;FEMALE;Dead;0.56;17;17;NA;NA;4;40
TCGA-22-4599;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;73;FEMALE;Dead;38.14;1161;1161;NA;NA;2;25
TCGA-22-4601;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T4;N0;stage III;73;FEMALE;Dead;34.72;1057;1057;Recurred/Progressed;17.25;2;60
TCGA-22-4604;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;73;MALE;Dead;13.11;399;NA;Recurred/Progressed;10.05;2;50
TCGA-22-4605;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;78;FEMALE;Dead;32;974;NA;NA;NA;4;75
TCGA-22-4607;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;75;MALE;Dead;19.28;587;587;NA;NA;3;20
TCGA-22-4609;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;81;MALE;Dead;9.56;291;NA;NA;NA;2;77
TCGA-22-4613;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;73;FEMALE;Dead;11.76;358;358;NA;NA;3;30
TCGA-22-5471;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;75;MALE;Alive;60.61;NA;964;Recurred/Progressed;7.52;4;50
TCGA-22-5472;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;67;MALE;Dead;64.88;1975;1975;Recurred/Progressed;29.63;4;35
TCGA-22-5473;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N0;;78;MALE;Dead;63.5;1933;NA;Recurred/Progressed;54.37;3;45
TCGA-22-5474;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;74;MALE;Dead;14.62;445;445;NA;NA;4;50
TCGA-22-5477;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;65;MALE;Dead;44.22;1346;1346;Recurred/Progressed;16.79;2;100
TCGA-22-5478;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 5;squamous-like c4;M0;T2;N0;stage I;79;MALE;Dead;0.79;24;24;NA;NA;4;NA
TCGA-22-5479;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;64;MALE;Dead;86.24;NA;1651;NA;NA;4;35
TCGA-22-5480;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;66;FEMALE;Dead;71.29;2170;2170;Recurred/Progressed;58.44;4;50
TCGA-22-5481;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;RNA cluster 12;M0;T2;N1;stage II;72;FEMALE;Dead;79.14;2409;NA;Recurred/Progressed;11.37;4;75
TCGA-22-5482;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;81;MALE;Dead;11.73;357;357;NA;NA;4;60
TCGA-22-5483;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);RNA cluster 3;M0;T1;N1;stage II;74;MALE;Dead;18.82;573;573;Recurred/Progressed;18.66;4;50
TCGA-22-5485;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;58;FEMALE;Dead;30.09;916;916;Recurred/Progressed;27.6;2;60
TCGA-22-5489;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;64;MALE;Dead;62.81;1912;1912;Recurred/Progressed;23.98;4;70
TCGA-22-5491;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;74;MALE;Dead;56.27;1713;1713;NA;NA;2;57
TCGA-22-5492;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N2;stage III;73;FEMALE;Dead;16.62;506;506;NA;NA;4;50
TCGA-22-A5C4;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;70;MALE;Alive;22.04;NA;29;DiseaseFree;22.04;4;80
TCGA-33-4532;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;68;MALE;Dead;128.91;NA;2524;NA;NA;2;53
TCGA-33-4533;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C10-GBM;Cluster 5;GBM-like c6;M0;T2;N0;stage I;76;FEMALE;Alive;133.64;NA;3469;DiseaseFree;133.64;4;50
TCGA-33-4538;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N2;stage III;66;MALE;Dead;97.86;2979;NA;NA;NA;2;51
TCGA-33-4547;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;68;MALE;Alive;79.47;NA;1311;DiseaseFree;79.47;3;40
TCGA-33-4566;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;40;MALE;Dead;173.69;5287;NA;NA;NA;2;20
TCGA-33-4582;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;55;MALE;Dead;103.45;3149;NA;Recurred/Progressed;96.02;2;86
TCGA-33-4583;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;73;MALE;Dead;151.15;NA;4299;NA;NA;4;46
TCGA-33-4586;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N2;stage III;57;MALE;Dead;14.06;428;NA;Recurred/Progressed;5.55;4;108
TCGA-33-4587;Lung Squamous Cell Carcinoma;Lung Small Cell Squamous Cell Carcinoma;;NA;;OV-like c1;RNA cluster 12;MX;T2;N0;stage I;63;FEMALE;Dead;54.4;1656;NA;NA;NA;4;NA
TCGA-33-4589;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 14 (HNSC);;M0;T2;N1;stage II;62;FEMALE;Dead;1.54;47;NA;NA;NA;2;45
TCGA-33-6737;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;71;MALE;Dead;19.74;601;NA;NA;NA;4;20
TCGA-33-6738;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;BRCA CIMP c7;squamous-like c4;MX;T1;N2;stage III;80;MALE;Alive;63.3;NA;822;DiseaseFree;63.3;4;50
TCGA-33-A4WN;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;60;MALE;Dead;4.7;143;NA;NA;NA;2;60
TCGA-33-A5GW;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N1;stage II;67;MALE;Dead;0.3;NA;9;NA;NA;4;50
TCGA-33-AAS8;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;59;FEMALE;Dead;36.6;1114;NA;NA;NA;4;60
TCGA-33-AASB;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;66;MALE;Dead;6.93;211;NA;Recurred/Progressed;0.99;2;40
TCGA-33-AASD;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;83;MALE;Dead;110.91;3376;NA;Recurred/Progressed;62.81;2;84
TCGA-33-AASI;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N1;stage II;65;FEMALE;Dead;44.15;1344;NA;NA;NA;4;60
TCGA-33-AASJ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;60;MALE;Dead;118.27;3600;NA;Recurred/Progressed;37.29;4;NA
TCGA-33-AASL;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;57;FEMALE;Dead;27.14;826;NA;Recurred/Progressed;4.89;2;60
TCGA-34-2596;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;70;MALE;Dead;2.63;80;80;NA;NA;3;60
TCGA-34-2600;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;76;FEMALE;Dead;61.56;1874;1874;NA;NA;4;50
TCGA-34-2604;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N0;stage I;81;FEMALE;Dead;31.47;958;958;NA;NA;2;132
TCGA-34-2605;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T4;N1;stage III;76;MALE;Dead;28.94;881;881;Recurred/Progressed;27.73;4;60
TCGA-34-2608;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N0;stage I;84;MALE;Dead;32.85;1000;1000;NA;NA;3;60
TCGA-34-2609;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N1;stage II;81;MALE;Dead;31.24;951;951;Recurred/Progressed;29.5;4;60
TCGA-34-5231;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;72;MALE;Dead;65.18;NA;1528;NA;NA;3;50
TCGA-34-5232;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N1;stage II;75;FEMALE;Alive;81.18;NA;1575;DiseaseFree;81.18;NA;NA
TCGA-34-5234;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Low purity c2;squamous-like c4;M0;T1;N0;stage I;71;FEMALE;Alive;74.61;NA;994;DiseaseFree;74.61;4;40
TCGA-34-5236;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N0;stage II;60;MALE;Dead;9.07;276;NA;Recurred/Progressed;3.71;NA;NA
TCGA-34-5239;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T4;N0;stage III;75;MALE;Alive;60.25;NA;329;Recurred/Progressed;50.26;NA;NA
TCGA-34-5240;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;73;FEMALE;Alive;50.62;NA;235;DiseaseFree;50.62;2;56
TCGA-34-5241;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;79;MALE;Dead;16.92;NA;428;NA;NA;3;25
TCGA-34-5927;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;70;FEMALE;Alive;44.71;NA;698;Recurred/Progressed;8.05;NA;NA
TCGA-34-5928;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;83;FEMALE;Alive;39.29;NA;169;DiseaseFree;39.29;3;40
TCGA-34-5929;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;78;FEMALE;Dead;4.96;151;NA;NA;NA;3;40
TCGA-34-7107;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage II;70;MALE;Dead;1.12;34;NA;NA;NA;4;NA
TCGA-34-8454;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N1;stage III;62;FEMALE;Alive;38.76;NA;166;DiseaseFree;38.76;4;90
TCGA-34-8455;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M1;T4;N0;stage IV;67;MALE;Dead;4.04;123;NA;NA;NA;4;50
TCGA-34-8456;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N1;stage II;71;FEMALE;Alive;26.41;NA;203;DiseaseFree;26.41;5;20
TCGA-34-A5IX;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;80;MALE;Alive;33.87;NA;636;DiseaseFree;33.87;4;NA
TCGA-35-3615;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;57;MALE;Alive;0.46;NA;14;DiseaseFree;0.46;1;NA
TCGA-35-4122;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;69;MALE;Alive;7.39;NA;225;DiseaseFree;7.39;4;45
TCGA-35-4123;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;38;MALE;Alive;5.98;NA;182;DiseaseFree;5.98;4;20
TCGA-35-5375;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;BRCA CIMP c7;squamous-like c4;M0;T2;N2;stage III;61;MALE;Alive;8.67;NA;264;DiseaseFree;8.67;4;35
TCGA-37-3783;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 14 (HNSC);squamous-like c4;M0;T3;N2;stage III;51;MALE;Alive;4.01;NA;122;DiseaseFree;4.01;NA;NA
TCGA-37-3789;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;;T2;N0;stage I;65;MALE;Alive;0.43;NA;13;DiseaseFree;0.43;1;NA
TCGA-37-3792;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;69;MALE;Alive;0.39;NA;12;DiseaseFree;0.39;1;NA
TCGA-37-4129;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C10-GBM;Low purity c2;GBM-like c6;M0;T1;N0;stage I;52;FEMALE;Alive;7.95;NA;213;DiseaseFree;7.95;4;30
TCGA-37-4130;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LAML-like c13;M0;T1;N0;stage I;56;MALE;Alive;8.11;NA;247;DiseaseFree;8.11;4;25
TCGA-37-4132;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;RNA cluster 3;M1;T2;N0;stage IV;61;FEMALE;Alive;7.46;NA;227;DiseaseFree;7.46;1;NA
TCGA-37-4133;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T4;N0;stage III;63;MALE;Alive;7.82;NA;238;DiseaseFree;7.82;4;40
TCGA-37-4135;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;RNA cluster 12;M0;T2;N0;stage I;68;MALE;Alive;6.8;NA;207;DiseaseFree;6.8;4;45
TCGA-37-4141;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;RNA cluster 3;M0;T1;N0;stage I;65;FEMALE;Alive;0.39;NA;12;DiseaseFree;0.39;1;NA
TCGA-37-5819;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;64;MALE;Alive;3.38;NA;103;DiseaseFree;3.38;4;45
TCGA-37-A5EL;Lung Squamous Cell Carcinoma;;;NA;;;;M0;T3;N0;stage II;53;MALE;Dead;37.55;NA;454;Recurred/Progressed;31.08;[Unknown];NA
TCGA-37-A5EM;Lung Squamous Cell Carcinoma;;;NA;;;;M0;T2;N0;stage II;49;MALE;Alive;28.48;NA;112;DiseaseFree;28.48;[Unknown];NA
TCGA-37-A5EN;Lung Squamous Cell Carcinoma;;;NA;;;;M0;T4;N2;stage III;59;MALE;Alive;21.68;NA;356;DiseaseFree;21.68;[Unknown];NA
TCGA-38-4625;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;66;FEMALE;Alive;97.67;NA;2973;DiseaseFree;97.67;2;50
TCGA-38-4626;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage II;57;FEMALE;Alive;120.7;NA;2595;Recurred/Progressed;82.72;2;40
TCGA-38-4627;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N1;stage II;64;FEMALE;Dead;37.68;1147;NA;NA;NA;4;NA
TCGA-38-4628;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;65;FEMALE;Dead;49.01;1492;NA;Recurred/Progressed;35.58;1;NA
TCGA-38-4629;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N0;stage II;68;MALE;Dead;28.38;864;NA;Recurred/Progressed;12.45;4;100
TCGA-38-4630;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;C6-UCEC;UCEC Serous c4;UCEC-like c11;M0;T2;N0;stage I;75;FEMALE;Dead;35.25;1073;NA;Recurred/Progressed;27.46;1;NA
TCGA-38-4631;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;72;FEMALE;Dead;11.63;354;NA;NA;NA;4;40
TCGA-38-4632;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T2;N1;stage IV;42;MALE;Dead;44.58;1357;NA;Recurred/Progressed;30.39;4;10
TCGA-38-6178;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;;T2;N2;stage III;70;FEMALE;Alive;14.72;NA;158;DiseaseFree;14.72;1;NA
TCGA-38-7271;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;72;FEMALE;Dead;26.28;800;NA;Recurred/Progressed;20.8;4;25
TCGA-38-A44F;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N0;stage I;80;MALE;Alive;4.37;NA;133;DiseaseFree;4.37;3;12
TCGA-39-5011;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;70;FEMALE;Alive;133.15;NA;1454;Recurred/Progressed;18.56;4;45
TCGA-39-5016;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;44;MALE;Alive;126.48;NA;2253;DiseaseFree;126.48;4;40
TCGA-39-5019;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;70;MALE;Alive;111.27;NA;1361;Recurred/Progressed;12.42;3;30
TCGA-39-5021;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;70;MALE;Dead;68.53;2086;2086;Recurred/Progressed;61.6;4;114
TCGA-39-5022;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;;M0;T2;N0;stage I;76;MALE;Dead;55.16;1679;NA;Recurred/Progressed;47.57;4;35
TCGA-39-5024;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N2;stage III;65;FEMALE;Alive;82.46;NA;2130;DiseaseFree;82.46;4;40
TCGA-39-5027;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;73;MALE;Alive;102.1;NA;1849;Recurred/Progressed;101.22;4;40
TCGA-39-5028;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T4;N1;stage III;75;MALE;Dead;1.71;52;52;NA;NA;3;30
TCGA-39-5029;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N2;stage III;67;MALE;Dead;24.31;740;NA;Recurred/Progressed;16.13;4;192
TCGA-39-5030;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N2;stage III;81;FEMALE;Dead;1.94;59;59;NA;NA;3;8
TCGA-39-5031;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;76;FEMALE;Dead;60.48;NA;833;NA;NA;4;60
TCGA-39-5034;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N0;stage II;73;FEMALE;Dead;36.37;1107;1107;Recurred/Progressed;11.56;4;84
TCGA-39-5035;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;72;FEMALE;Alive;68.33;NA;474;DiseaseFree;68.33;4;47
TCGA-39-5036;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;73;MALE;Alive;71.12;NA;1084;DiseaseFree;71.12;4;63
TCGA-39-5037;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N1;stage II;65;MALE;Alive;55.52;NA;24;DiseaseFree;55.52;2;26
TCGA-39-5039;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N0;stage II;76;MALE;Dead;17.87;544;544;NA;NA;3;64
TCGA-39-5040;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;BRCA CIMP c7;;M0;T2;N2;stage III;59;MALE;Dead;17.05;519;NA;Recurred/Progressed;14.52;4;60
TCGA-43-2576;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N2;stage III;62;FEMALE;Alive;40.18;NA;556;DiseaseFree;40.18;4;20
TCGA-43-2578;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;RNA cluster 3;M0;T1;N0;stage I;59;FEMALE;Dead;22.47;NA;550;NA;NA;4;64
TCGA-43-2581;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N1;stage III;47;FEMALE;Alive;38.63;NA;399;DiseaseFree;38.63;2;30
TCGA-43-3394;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;52;MALE;Dead;39.09;NA;352;Recurred/Progressed;18.13;2;15
TCGA-43-3920;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;71;MALE;Alive;33.08;NA;268;DiseaseFree;33.08;4;50
TCGA-43-5668;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 6;RNA cluster 5;M0;T1;N1;stage II;78;MALE;Dead;18.36;NA;258;Recurred/Progressed;15.44;3;20
TCGA-43-5670;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N0;stage II;70;MALE;Alive;27.89;NA;549;DiseaseFree;27.89;3;30
TCGA-43-6143;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;primitive;C1-LUAD-enriched;Cluster 5;RNA cluster 12;M0;T2;N0;stage I;70;MALE;Alive;22.96;NA;214;DiseaseFree;22.96;4;114
TCGA-43-6647;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;MX;T2;N1;stage II;69;FEMALE;Alive;24.87;NA;183;DiseaseFree;24.87;4;36
TCGA-43-6770;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;MX;T2;N0;stage I;59;FEMALE;Alive;21.45;NA;85;DiseaseFree;21.45;2;34
TCGA-43-6771;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 6;squamous-like c4;MX;T2;N0;stage I;85;MALE;Dead;5.45;166;NA;Recurred/Progressed;5.06;3;40
TCGA-43-6773;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;MX;T2;N1;stage II;76;MALE;Dead;3.81;116;NA;NA;NA;3;NA
TCGA-43-7656;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Low purity c2;RNA cluster 12;MX;T1;N0;stage I;71;MALE;Alive;19.58;NA;212;DiseaseFree;19.58;4;45
TCGA-43-7657;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;MX;T1;N0;stage I;68;FEMALE;Alive;7.75;NA;48;DiseaseFree;7.75;4;45
TCGA-43-7658;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;75;FEMALE;Dead;78.12;NA;2023;Recurred/Progressed;75.72;4;12
TCGA-43-8115;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T2;N1;stage II;72;FEMALE;Alive;13.37;NA;202;DiseaseFree;13.37;4;55.83
TCGA-43-8116;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N0;stage I;73;MALE;Alive;11.76;NA;193;DiseaseFree;11.76;2;35
TCGA-43-8118;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;55;FEMALE;Dead;2.92;89;NA;NA;NA;2;20
TCGA-43-A474;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;66;MALE;Alive;11.6;NA;262;DiseaseFree;11.6;4;47
TCGA-43-A475;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;67;FEMALE;Alive;9.72;NA;206;DiseaseFree;9.72;4;100
TCGA-43-A56U;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;76;FEMALE;Alive;14.19;NA;55;DiseaseFree;14.19;4;20.5
TCGA-43-A56V;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N2;stage III;61;MALE;Alive;12.02;NA;154;Recurred/Progressed;11.66;4;48
TCGA-44-2655;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;65;FEMALE;Alive;43.5;NA;575;Recurred/Progressed;33.15;3;30
TCGA-44-2656;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;59;MALE;Alive;46.94;NA;582;Recurred/Progressed;18.66;4;23
TCGA-44-2657;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;NX;stage I;74;FEMALE;Alive;44.38;NA;400;DiseaseFree;44.38;4;25
TCGA-44-2659;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;;;LUAD-like c10;M0;T1;N1;stage II;65;FEMALE;Alive;44.91;NA;529;Recurred/Progressed;37.65;4;57
TCGA-44-2661;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;69;FEMALE;Alive;38.07;NA;103;DiseaseFree;38.07;1;NA
TCGA-44-2662;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;65;MALE;Alive;42.05;NA;480;Recurred/Progressed;8.05;3;56
TCGA-44-2664;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;66;FEMALE;Alive;41.1;NA;383;Recurred/Progressed;27.33;2;23
TCGA-44-2665;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;55;FEMALE;Alive;42.74;NA;400;DiseaseFree;42.74;1;NA
TCGA-44-2666;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;43;MALE;Dead;3.19;97;97;NA;NA;2;30
TCGA-44-2668;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;51;MALE;Dead;25;NA;246;Recurred/Progressed;14.22;4;60
TCGA-44-3396;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;74;FEMALE;Alive;37.12;NA;311;DiseaseFree;37.12;2;50
TCGA-44-3398;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;77;FEMALE;Alive;38.21;NA;253;DiseaseFree;38.21;4;60
TCGA-44-3917;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;33;FEMALE;Alive;38.86;NA;392;DiseaseFree;38.86;2;16
TCGA-44-3918;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;60;FEMALE;Alive;34.03;NA;197;Recurred/Progressed;16.79;3;20
TCGA-44-3919;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;71;FEMALE;Dead;33.71;NA;190;Recurred/Progressed;32.33;1;NA
TCGA-44-4112;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;60;FEMALE;Dead;26.54;NA;141;Recurred/Progressed;20.34;3;30
TCGA-44-5643;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N2;stage III;53;MALE;Alive;33.28;NA;106;DiseaseFree;33.28;2;20
TCGA-44-5644;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;;T2;N0;stage I;51;FEMALE;Alive;28.35;NA;498;DiseaseFree;28.35;2;17.5
TCGA-44-5645;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;;T1;NX;stage I;61;FEMALE;Alive;27.99;NA;208;DiseaseFree;27.99;3;5
TCGA-44-6144;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;;M0;T1;N0;stage I;58;MALE;Alive;23.75;NA;9;Recurred/Progressed;13.11;2;67.5
TCGA-44-6145;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;62;FEMALE;Alive;19.55;NA;103;DiseaseFree;19.55;4;75
TCGA-44-6146;Lung Adenocarcinoma;Lung Mucinous Adenocarcinoma;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N0;stage II;64;MALE;Alive;23.92;NA;302;Recurred/Progressed;20.73;3;15
TCGA-44-6147;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;NX;stage I;67;FEMALE;Alive;27.76;NA;236;DiseaseFree;27.76;3;NA
TCGA-44-6148;Lung Adenocarcinoma;Lung Mucinous Adenocarcinoma;;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T1;N0;stage I;60;MALE;Alive;23.13;NA;96;DiseaseFree;23.13;3;60
TCGA-44-6774;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N2;stage III;56;FEMALE;Alive;21.62;NA;166;DiseaseFree;21.62;2;20
TCGA-44-6775;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;72;FEMALE;Alive;23.16;NA;83;Recurred/Progressed;22.47;4;25
TCGA-44-6776;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;60;FEMALE;Alive;85.94;NA;1938;DiseaseFree;85.94;4;45
TCGA-44-6777;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;NX;stage I;85;FEMALE;Dead;32.42;987;NA;NA;NA;4;64
TCGA-44-6778;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;MX;T1;N0;stage I;59;MALE;Alive;61.24;NA;1110;DiseaseFree;61.24;4;15
TCGA-44-6779;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N1;stage II;50;FEMALE;Dead;16.43;500;NA;Recurred/Progressed;7.62;4;15
TCGA-44-7659;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;70;MALE;Alive;22.7;NA;299;DiseaseFree;22.7;2;40
TCGA-44-7660;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;OV-like c1;squamous-like c4;MX;T2;N0;stage I;72;MALE;Alive;19.45;NA;162;Recurred/Progressed;8.31;2;124
TCGA-44-7661;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;69;FEMALE;Dead;18.3;NA;153;Recurred/Progressed;11.01;3;22
TCGA-44-7662;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;61;MALE;Alive;7.16;NA;50;DiseaseFree;7.16;2;50
TCGA-44-7667;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T3;N0;stage II;49;FEMALE;Alive;36.04;NA;557;DiseaseFree;36.04;2;50
TCGA-44-7669;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N1;stage II;59;MALE;Dead;18.86;574;NA;Recurred/Progressed;17.25;2;20
TCGA-44-7670;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N1;stage II;47;FEMALE;Alive;28.98;NA;531;DiseaseFree;28.98;2;30
TCGA-44-7671;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;64;MALE;Alive;29.2;NA;535;Recurred/Progressed;29.01;3;NA
TCGA-44-7672;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;52;FEMALE;Alive;23.62;NA;418;DiseaseFree;23.62;2;20
TCGA-44-8117;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;54;FEMALE;Alive;12.65;NA;259;DiseaseFree;12.65;4;54
TCGA-44-8119;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T3;N0;stage II;73;MALE;Alive;9.36;NA;99;DiseaseFree;9.36;2;50
TCGA-44-8120;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;58;MALE;Alive;8.54;NA;169;DiseaseFree;8.54;5;30
TCGA-44-A479;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;73;FEMALE;Alive;15.97;NA;256;Recurred/Progressed;14.36;4;40
TCGA-44-A47A;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;78;FEMALE;Alive;15.31;NA;202;Recurred/Progressed;13.14;4;80
TCGA-44-A47B;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;79;MALE;Alive;9.43;NA;105;DiseaseFree;9.43;3;4.5
TCGA-44-A47F;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;74;MALE;Alive;11.07;NA;246;DiseaseFree;11.07;3;20
TCGA-44-A47G;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;73;FEMALE;Alive;11.53;NA;135;DiseaseFree;11.53;4;28
TCGA-44-A4SS;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;73;MALE;Alive;13.63;NA;114;DiseaseFree;13.63;4;90
TCGA-44-A4SU;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;67;FEMALE;Dead;13.44;NA;76;Recurred/Progressed;8.54;4;50
TCGA-46-3765;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;59;FEMALE;Alive;13.3;NA;396;DiseaseFree;13.3;2;NA
TCGA-46-3766;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;62;FEMALE;Alive;12.16;NA;365;DiseaseFree;12.16;4;NA
TCGA-46-3767;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;76;MALE;Alive;13.01;NA;396;DiseaseFree;13.01;3;NA
TCGA-46-3768;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N1;stage III;58;MALE;Dead;9.82;299;NA;NA;NA;4;NA
TCGA-46-3769;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T4;N0;stage II;57;MALE;Alive;4.43;NA;121;DiseaseFree;4.43;4;NA
TCGA-46-6025;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;71;MALE;Alive;10.64;NA;206;DiseaseFree;10.64;4;NA
TCGA-46-6026;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;81;MALE;Alive;13.9;NA;18;DiseaseFree;13.9;3;NA
TCGA-49-4486;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;72;MALE;Dead;76.15;2318;NA;Recurred/Progressed;67.18;3;17.5
TCGA-49-4487;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;72;FEMALE;Dead;28.09;855;NA;Recurred/Progressed;22.9;4;40
TCGA-49-4488;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;74;FEMALE;Dead;28.55;869;NA;Recurred/Progressed;20.83;3;NA
TCGA-49-4490;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N2;stage III;45;FEMALE;Dead;12.65;385;NA;NA;NA;3;5
TCGA-49-4494;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N2;stage III;77;MALE;Dead;35.51;1081;NA;NA;NA;3;50
TCGA-49-4501;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;67;FEMALE;Dead;46.68;1421;NA;Recurred/Progressed;17.9;1;NA
TCGA-49-4505;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;61;FEMALE;Dead;14.06;428;NA;Recurred/Progressed;13.7;4;74
TCGA-49-4506;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;68;FEMALE;Dead;32.82;999;NA;Recurred/Progressed;22.73;2;100
TCGA-49-4507;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N1;stage III;73;FEMALE;Dead;8.8;268;NA;Recurred/Progressed;5.19;4;78
TCGA-49-4510;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;51;FEMALE;Dead;29.43;896;NA;Recurred/Progressed;16.49;2;55.5
TCGA-49-4512;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N2;stage III;69;FEMALE;Dead;29.73;905;157;NA;NA;1;NA
TCGA-49-4514;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;79;FEMALE;Alive;55.85;NA;1314;DiseaseFree;55.85;3;65
TCGA-49-6742;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;70;MALE;Dead;16.03;NA;1678;Recurred/Progressed;7.03;3;10
TCGA-49-6743;Lung Adenocarcinoma;Lung Clear Cell Adenocarcinoma;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N2;stage III;81;FEMALE;Alive;53.25;NA;369;DiseaseFree;53.25;4;50
TCGA-49-6744;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N1;stage II;64;FEMALE;Alive;55.29;NA;890;DiseaseFree;55.29;4;20
TCGA-49-6745;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;82;MALE;Alive;17.15;NA;156;DiseaseFree;17.15;4;20
TCGA-49-6761;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T1;N2;stage III;68;FEMALE;Alive;11.63;NA;1;DiseaseFree;11.63;4;50
TCGA-49-6767;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T3;N0;stage II;46;FEMALE;Alive;22.24;NA;0;DiseaseFree;22.24;2;30
TCGA-49-AAQV;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;MX;T1;N1;stage II;63;FEMALE;Dead;22.24;677;NA;Recurred/Progressed;16.72;1;NA
TCGA-49-AAR0;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;57;MALE;Alive;156.54;NA;4415;DiseaseFree;156.54;2;37
TCGA-49-AAR2;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;MX;T2;N0;stage I;64;MALE;Alive;73.06;NA;1945;DiseaseFree;73.06;4;NA
TCGA-49-AAR3;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N1;stage II;69;MALE;Alive;62.19;NA;1893;Recurred/Progressed;62.19;[Unknown];NA
TCGA-49-AAR4;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N2;stage III;51;MALE;Dead;28.88;879;NA;NA;NA;2;35
TCGA-49-AAR9;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N0;stage II;61;MALE;Dead;8.54;260;NA;NA;NA;2;NA
TCGA-49-AARE;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;51;FEMALE;Dead;40.37;1229;NA;Recurred/Progressed;12.75;4;15
TCGA-49-AARN;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;56;FEMALE;Dead;37.29;1135;NA;NA;NA;5;NA
TCGA-49-AARO;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;MX;T1;N0;stage I;39;FEMALE;Alive;123.49;NA;3755;Recurred/Progressed;115.67;2;NA
TCGA-49-AARQ;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;41;FEMALE;Alive;221.16;NA;6443;DiseaseFree;221.16;4;60
TCGA-49-AARR;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;68;MALE;Alive;163.99;NA;4630;Recurred/Progressed;158.08;3;NA
TCGA-4B-A93V;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;52;FEMALE;Dead;9.86;NA;254;Recurred/Progressed;8.25;4;30
TCGA-50-5044;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T4;N1;stage III;72;FEMALE;Dead;20.5;624;NA;Recurred/Progressed;15.87;NA;NA
TCGA-50-5045;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;;M0;T2;N1;stage I;57;FEMALE;Dead;71.42;2174;NA;Recurred/Progressed;47.08;NA;NA
TCGA-50-5049;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;70;MALE;Alive;101.64;NA;1485;Recurred/Progressed;83.57;NA;NA
TCGA-50-5051;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;42;FEMALE;Dead;15.7;NA;455;Recurred/Progressed;6.04;4;30
TCGA-50-5055;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C10-GBM;Low purity c2;LUAD-like c10;M0;T1;N1;stage II;79;FEMALE;Dead;60.12;NA;785;Recurred/Progressed;25.33;NA;NA
TCGA-50-5066;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;72;MALE;Alive;47.37;NA;297;Recurred/Progressed;15.67;1;NA
TCGA-50-5066;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;72;MALE;Alive;47.37;NA;297;Recurred/Progressed;15.67;1;NA
TCGA-50-5068;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N1;stage II;59;FEMALE;Dead;49.24;1499;1499;Recurred/Progressed;22.54;NA;NA
TCGA-50-5072;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;74;MALE;Dead;8.21;NA;246;Recurred/Progressed;7;3;15
TCGA-50-5930;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 5;;M0;T2;N2;stage III;47;MALE;Dead;9.26;282;NA;Recurred/Progressed;5.81;NA;NA
TCGA-50-5931;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;RNA cluster 12;M0;T2;N0;stage I;75;FEMALE;Dead;14.26;434;267;Recurred/Progressed;13.96;4;40
TCGA-50-5932;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;75;MALE;Dead;40.57;1235;1091;Recurred/Progressed;35.81;NA;NA
TCGA-50-5933;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T4;N2;stage III;72;MALE;Dead;78.61;2393;2370;NA;NA;NA;NA
TCGA-50-5935;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;86;FEMALE;Dead;21.45;653;653;NA;NA;NA;NA
TCGA-50-5936;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;58;MALE;Dead;8.44;257;NA;Recurred/Progressed;4.93;NA;NA
TCGA-50-5939;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;85;MALE;Dead;15.11;460;NA;NA;NA;3;15
TCGA-50-5941;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;55;FEMALE;Alive;48.42;NA;285;DiseaseFree;48.42;2;25
TCGA-50-5942;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;67;FEMALE;Alive;60.68;NA;136;Recurred/Progressed;45.27;4;30
TCGA-50-5944;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;69;FEMALE;Alive;57.49;NA;373;DiseaseFree;57.49;NA;NA
TCGA-50-5946;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;62;MALE;Alive;53.12;NA;349;Recurred/Progressed;26.64;4;NA
TCGA-50-5946;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;62;MALE;Alive;53.12;NA;349;Recurred/Progressed;26.64;4;NA
TCGA-50-6590;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;72;FEMALE;Dead;42.31;1288;NA;NA;NA;4;50
TCGA-50-6591;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;GBM-like c6;M1;T2;N0;stage IV;63;FEMALE;Dead;3.91;119;NA;NA;NA;1;NA
TCGA-50-6592;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;71;FEMALE;Dead;25.53;777;NA;NA;NA;4;NA
TCGA-50-6593;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N2;stage III;49;FEMALE;Dead;11.04;336;NA;Recurred/Progressed;8.74;4;NA
TCGA-50-6594;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N2;stage III;79;FEMALE;Dead;12.16;370;NA;Recurred/Progressed;9.36;4;NA
TCGA-50-6595;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;squamous-like c4;M0;T2;N2;stage III;74;FEMALE;Dead;6.21;189;NA;Recurred/Progressed;5.98;3;NA
TCGA-50-6597;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;79;FEMALE;Dead;41.66;NA;1015;NA;NA;1;NA
TCGA-50-6673;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;84;FEMALE;Dead;0.72;22;NA;NA;NA;1;NA
TCGA-50-7109;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;60;MALE;Dead;10.12;NA;255;Recurred/Progressed;0.49;2;120
TCGA-50-8457;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;;M0;T1;N0;stage I;63;FEMALE;Alive;36.96;NA;44;DiseaseFree;36.96;4;30
TCGA-50-8459;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;;NA;;Cluster 5;;M0;T3;N0;stage II;68;MALE;Alive;36.76;NA;231;Recurred/Progressed;14.19;2;10
TCGA-50-8460;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;;M0;T1;N0;stage I;74;MALE;Alive;27.23;NA;105;DiseaseFree;27.23;[Unknown];NA
TCGA-51-4079;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;;T2;N0;stage I;73;FEMALE;Dead;0.39;12;NA;NA;NA;4;25
TCGA-51-4080;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;;T4;N1;stage III;65;MALE;Dead;0.39;12;NA;NA;NA;4;NA
TCGA-51-4081;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;55;MALE;Alive;29.93;NA;63;DiseaseFree;29.93;2;80
TCGA-51-6867;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;72;FEMALE;Dead;60.97;1856;NA;Recurred/Progressed;25.89;4;40
TCGA-52-7622;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N0;stage I;62;FEMALE;Alive;28.32;NA;541;DiseaseFree;28.32;4;22
TCGA-52-7809;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;Cluster 5;;M0;T2;N0;stage I;74;MALE;Dead;5.45;166;NA;NA;NA;2;60
TCGA-52-7810;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N0;stage II;60;FEMALE;Alive;30.32;NA;923;DiseaseFree;30.32;3;20
TCGA-52-7811;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N0;stage I;67;MALE;Dead;8.74;266;NA;Recurred/Progressed;5.03;2;50
TCGA-52-7812;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;;M0;T2;N2;stage II;68;MALE;Dead;27.43;835;NA;Recurred/Progressed;25.99;4;30
TCGA-53-7624;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C8-BLCA;Cluster 5;BLCA nonsquamous-like c1;M1;T2;N0;stage IV;40;FEMALE;Dead;34.26;1043;NA;Recurred/Progressed;13.14;2;50
TCGA-53-7626;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N1;stage II;76;FEMALE;Dead;30.52;929;NA;Recurred/Progressed;28.42;4;35
TCGA-53-7813;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T4;N0;stage III;51;FEMALE;Alive;13.93;NA;418;DiseaseFree;13.93;4;35
TCGA-53-A4EZ;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;MX;T2;N1;stage II;63;MALE;Alive;35.18;NA;280;DiseaseFree;35.18;3;40
TCGA-55-1592;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;65;MALE;Dead;23.03;701;NA;Recurred/Progressed;14.85;4;NA
TCGA-55-1594;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;68;MALE;Alive;38.7;NA;1178;DiseaseFree;38.7;2;NA
TCGA-55-1595;Lung Adenocarcinoma;Lung Clear Cell Adenocarcinoma;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;74;FEMALE;Alive;48.59;NA;1479;DiseaseFree;48.59;4;NA
TCGA-55-1596;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;55;MALE;Alive;67.84;NA;1375;DiseaseFree;67.84;2;50
TCGA-55-5899;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N1;stage I;58;MALE;Alive;30.55;NA;87;DiseaseFree;30.55;2;NA
TCGA-55-6543;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Mucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;60;FEMALE;Alive;14.29;NA;2;DiseaseFree;14.29;4;60
TCGA-55-6642;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;63;MALE;Alive;80.45;NA;993;DiseaseFree;80.45;2;NA
TCGA-55-6712;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N1;stage II;71;MALE;Dead;5.62;NA;24;NA;NA;4;NA
TCGA-55-6968;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M1;T1;N0;stage IV;61;MALE;Dead;42.48;1293;NA;NA;NA;2;NA
TCGA-55-6969;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;52;MALE;Alive;40.7;NA;1239;DiseaseFree;40.7;4;NA
TCGA-55-6970;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N2;stage III;67;FEMALE;Dead;15.24;464;NA;Recurred/Progressed;15.01;4;NA
TCGA-55-6971;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;59;FEMALE;Alive;45.99;NA;25;DiseaseFree;45.99;4;60
TCGA-55-6972;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Magnoid;NA;;Low purity c2;LUAD-like c10;M0;T2;N0;stage I;72;MALE;Dead;53.61;NA;1475;NA;NA;2;NA
TCGA-55-6975;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;61;MALE;Dead;3.88;118;NA;NA;NA;4;NA
TCGA-55-6978;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage II;81;MALE;Dead;5.78;176;NA;Recurred/Progressed;1.38;1;NA
TCGA-55-6979;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;59;FEMALE;Dead;7.79;237;NA;Recurred/Progressed;6.41;3;NA
TCGA-55-6980;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;56;MALE;Alive;69.28;NA;67;DiseaseFree;69.28;1;NA
TCGA-55-6981;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N2;stage III;53;FEMALE;Dead;45.3;1379;NA;NA;NA;3;NA
TCGA-55-6982;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;79;FEMALE;Dead;32.69;995;NA;Recurred/Progressed;6.01;1;NA
TCGA-55-6983;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;Magnoid;NA;;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;81;MALE;Alive;92.74;NA;1826;DiseaseFree;92.74;4;60
TCGA-55-6984;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;BRCA non-CIMP c9;LUAD-like c10;M0;T2;N1;stage II;71;FEMALE;Dead;24.97;760;NA;Recurred/Progressed;23.78;NA;NA
TCGA-55-6985;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;58;FEMALE;Alive;40.51;NA;1233;DiseaseFree;40.51;4;50
TCGA-55-6986;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;74;FEMALE;Alive;107.13;NA;2151;DiseaseFree;107.13;1;NA
TCGA-55-6987;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;77;MALE;Alive;70.2;NA;1170;DiseaseFree;70.2;4;NA
TCGA-55-7227;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;MX;T3;N1;stage III;77;MALE;Dead;31.27;NA;53;Recurred/Progressed;8.38;3;NA
TCGA-55-7281;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;70;FEMALE;Alive;28.65;NA;18;Recurred/Progressed;11.14;4;20
TCGA-55-7283;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;;Cluster 6;LUAD-like c10;MX;T3;N2;stage III;76;FEMALE;Alive;20.01;NA;35;DiseaseFree;20.01;3;5
TCGA-55-7284;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;Cluster 5;LUAD-like c10;MX;T3;N0;stage II;74;MALE;Dead;7.98;NA;121;Recurred/Progressed;7.59;3;NA
TCGA-55-7570;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;RNA cluster 3;MX;T1;N0;stage I;60;MALE;Alive;27.07;NA;6;DiseaseFree;27.07;2;NA
TCGA-55-7573;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;72;FEMALE;Alive;16;NA;4;DiseaseFree;16;3;NA
TCGA-55-7574;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;64;FEMALE;Dead;32.69;NA;95;Recurred/Progressed;15.7;4;2
TCGA-55-7576;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;54;MALE;Alive;22.01;NA;40;DiseaseFree;22.01;2;NA
TCGA-55-7724;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;;Cluster 5;squamous-like c4;MX;T2;N0;stage I;76;FEMALE;Alive;23.16;NA;0;DiseaseFree;23.16;4;50
TCGA-55-7725;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;68;FEMALE;Alive;14.52;NA;39;DiseaseFree;14.52;3;16
TCGA-55-7726;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;;Cluster 5;squamous-like c4;MX;T1;N0;stage I;72;FEMALE;Alive;21.42;NA;39;DiseaseFree;21.42;3;30
TCGA-55-7727;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;;Cluster 6;LUAD-like c10;MX;T1;N2;stage III;70;MALE;Alive;3.91;NA;34;DiseaseFree;3.91;2;NA
TCGA-55-7728;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;64;FEMALE;Alive;23.13;NA;24;DiseaseFree;23.13;4;30
TCGA-55-7815;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;76;MALE;Alive;25.39;NA;54;Recurred/Progressed;19.45;1;NA
TCGA-55-7816;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;MX;TX;NX;stage IV;49;FEMALE;Dead;15.37;NA;44;NA;NA;1;NA
TCGA-55-7903;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;64;MALE;Alive;18.63;NA;19;DiseaseFree;18.63;2;40
TCGA-55-7907;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;;Cluster 6;LUAD-like c10;MX;T2;N1;stage II;77;MALE;Dead;11.27;NA;16;Recurred/Progressed;9.66;3;80
TCGA-55-7910;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T2;N0;stage II;50;FEMALE;Alive;34.17;NA;203;Recurred/Progressed;33.44;4;15
TCGA-55-7911;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;70;FEMALE;Alive;17.64;NA;21;Recurred/Progressed;16.92;3;96
TCGA-55-7913;Lung Adenocarcinoma;;;NA;;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;61;FEMALE;Dead;18.43;NA;62;Recurred/Progressed;15.77;2;40
TCGA-55-7914;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;;Cluster 6;LUAD-like c10;MX;T1;N1;stage II;71;FEMALE;Dead;6.14;NA;3;NA;NA;2;5
TCGA-55-7994;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;MX;T3;N0;stage II;81;MALE;Alive;19.81;NA;31;DiseaseFree;19.81;2;28
TCGA-55-7995;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;BRCA basal-like c8;LUAD-like c10;M0;T1;N0;stage I;73;FEMALE;Alive;29.2;NA;5;Recurred/Progressed;15.37;4;60
TCGA-55-8085;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;64;MALE;Alive;29.7;NA;33;DiseaseFree;29.7;2;NA
TCGA-55-8087;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;59;FEMALE;Alive;15.18;NA;21;DiseaseFree;15.18;1;NA
TCGA-55-8089;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;56;MALE;Dead;23.06;NA;100;NA;NA;2;97
TCGA-55-8090;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;80;MALE;Dead;19.65;NA;6;Recurred/Progressed;18;2;NA
TCGA-55-8091;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;74;MALE;Alive;19.71;NA;43;DiseaseFree;19.71;3;NA
TCGA-55-8092;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;MX;T3;N0;stage II;75;MALE;Dead;5.06;NA;26;Recurred/Progressed;4.17;4;40
TCGA-55-8094;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M1;T2;N0;stage IV;51;MALE;Alive;17.77;NA;4;DiseaseFree;17.77;4;70
TCGA-55-8096;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;LUAD-like c10;MX;T2;N0;stage I;67;FEMALE;Dead;23.62;NA;47;Recurred/Progressed;18.59;2;104
TCGA-55-8097;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;60;FEMALE;Alive;15.64;NA;15;DiseaseFree;15.64;4;35
TCGA-55-8203;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;69;FEMALE;Alive;17.97;NA;4;DiseaseFree;17.97;2;50
TCGA-55-8204;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;squamous-like c4;MX;T2;N0;stage I;87;FEMALE;Alive;16.92;NA;0;DiseaseFree;16.92;3;NA
TCGA-55-8205;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage II;76;FEMALE;Alive;19.68;NA;33;Recurred/Progressed;16.26;4;30
TCGA-55-8206;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;56;MALE;Alive;29.17;NA;46;DiseaseFree;29.17;1;NA
TCGA-55-8207;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;73;MALE;Alive;32.1;NA;66;DiseaseFree;32.1;3;NA
TCGA-55-8208;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;73;FEMALE;Alive;22.14;NA;0;Recurred/Progressed;16.79;2;50
TCGA-55-8299;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;LUAD-like c10;MX;T1;N0;stage I;61;FEMALE;Dead;15.41;NA;216;Recurred/Progressed;9;4;20
TCGA-55-8301;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;58;MALE;Alive;17.54;NA;44;Recurred/Progressed;7.82;2;100
TCGA-55-8302;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;;MX;T2;N0;stage I;54;MALE;Alive;15.7;NA;23;DiseaseFree;15.7;2;59
TCGA-55-8505;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N2;stage III;62;MALE;Alive;14.45;NA;29;DiseaseFree;14.45;1;NA
TCGA-55-8506;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N0;stage II;62;FEMALE;Alive;0.36;NA;11;DiseaseFree;0.36;2;NA
TCGA-55-8507;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;53;MALE;Alive;13.73;NA;8;DiseaseFree;13.73;2;120
TCGA-55-8508;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;;NA;;;;MX;T2;N1;stage II;60;FEMALE;Alive;20.27;NA;15;DiseaseFree;20.27;2;NA
TCGA-55-8510;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;55;FEMALE;Alive;17.71;NA;228;DiseaseFree;17.71;2;NA
TCGA-55-8511;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;73;FEMALE;Alive;18.13;NA;9;Recurred/Progressed;15.11;2;58
TCGA-55-8512;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;;;M1;T1;N1;stage IV;41;MALE;Dead;19.94;NA;3;NA;NA;2;19
TCGA-55-8513;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;;NA;;;;MX;T3;N0;stage II;77;FEMALE;Alive;25.99;NA;146;Recurred/Progressed;10.41;1;NA
TCGA-55-8514;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;70;FEMALE;Alive;17.08;NA;202;DiseaseFree;17.08;4;20
TCGA-55-8614;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;76;MALE;Alive;17.61;NA;41;DiseaseFree;17.61;3;40
TCGA-55-8615;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N2;stage III;67;MALE;Alive;14.65;NA;15;Recurred/Progressed;7.36;2;67
TCGA-55-8616;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;58;FEMALE;Alive;1.58;NA;48;DiseaseFree;1.58;4;NA
TCGA-55-8619;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;;NA;;;;MX;T3;N0;stage II;72;FEMALE;Alive;13.67;NA;49;DiseaseFree;13.67;1;NA
TCGA-55-8620;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M1;T1;N1;stage IV;60;MALE;Dead;12.32;NA;66;NA;NA;4;154
TCGA-55-8621;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;75;FEMALE;Alive;16.92;NA;106;DiseaseFree;16.92;4;30
TCGA-55-A48X;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N1;stage II;63;FEMALE;Alive;22.63;NA;33;Recurred/Progressed;20.2;4;36
TCGA-55-A48Y;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;69;MALE;Alive;20.7;NA;42;DiseaseFree;20.7;2;50
TCGA-55-A48Z;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;MX;T1;N3;stage III;60;FEMALE;Alive;21.39;NA;29;Recurred/Progressed;17.61;4;40
TCGA-55-A490;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;78;MALE;Dead;3.25;NA;48;NA;NA;3;34
TCGA-55-A491;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;81;FEMALE;Alive;20.57;NA;0;DiseaseFree;20.57;3;45
TCGA-55-A492;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;70;FEMALE;Alive;19.58;NA;1;DiseaseFree;19.58;3;35
TCGA-55-A493;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;54;FEMALE;Alive;0.92;NA;28;DiseaseFree;0.92;2;53
TCGA-55-A494;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;61;FEMALE;Alive;15.8;NA;5;DiseaseFree;15.8;3;7
TCGA-55-A4DF;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;88;MALE;Dead;20.17;NA;47;Recurred/Progressed;16.92;3;60
TCGA-55-A4DG;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;71;MALE;Alive;19.97;NA;162;DiseaseFree;19.97;4;100
TCGA-55-A57B;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;80;FEMALE;Alive;17.94;NA;21;DiseaseFree;17.94;1;NA
TCGA-56-1622;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;58;MALE;Dead;28.94;881;NA;NA;NA;4;86
TCGA-56-5897;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Low purity c2;squamous-like c4;MX;T1;N0;stage I;74;MALE;Alive;12.42;NA;3;DiseaseFree;12.42;3;NA
TCGA-56-5898;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;69;MALE;Alive;18.23;NA;0;DiseaseFree;18.23;2;NA
TCGA-56-6545;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;77;FEMALE;Alive;21.88;NA;62;DiseaseFree;21.88;4;NA
TCGA-56-6546;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 5;RNA cluster 2;MX;T2;N0;stage II;67;MALE;Dead;NA;NA;NA;NA;NA;4;NA
TCGA-56-7221;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;79;MALE;Alive;19.97;NA;30;DiseaseFree;19.97;3;25
TCGA-56-7222;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;60;MALE;Dead;18.46;NA;13;Recurred/Progressed;14.03;2;23
TCGA-56-7223;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);RNA cluster 3;MX;T3;N1;stage III;66;MALE;Dead;14.52;NA;30;Recurred/Progressed;4.34;4;NA
TCGA-56-7579;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N1;stage III;61;MALE;Dead;31.24;NA;44;Recurred/Progressed;4.89;4;2
TCGA-56-7580;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;squamous-like c4;M0;T2;N0;stage I;84;MALE;Alive;30.39;NA;40;DiseaseFree;30.39;3;NA
TCGA-56-7582;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;83;MALE;Alive;19.74;NA;26;DiseaseFree;19.74;3;NA
TCGA-56-7730;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage II;73;MALE;Dead;6.5;NA;6;NA;NA;2;NA
TCGA-56-7731;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T2;N0;stage I;66;FEMALE;Dead;0.1;NA;0;NA;NA;4;100
TCGA-56-7822;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;squamous-like c4;M0;T2;N1;stage II;75;MALE;Dead;17.48;NA;1;Recurred/Progressed;9.89;4;60
TCGA-56-7823;Lung Squamous Cell Carcinoma;;;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N1;stage II;58;FEMALE;Alive;33.21;NA;77;DiseaseFree;33.21;4;80
TCGA-56-8082;Lung Squamous Cell Carcinoma;;;NA;;Cluster 5;;MX;T2;N0;stage II;80;FEMALE;Alive;14.95;NA;26;DiseaseFree;14.95;3;NA
TCGA-56-8083;Lung Squamous Cell Carcinoma;;;NA;;Cluster 5;;MX;T2;N0;stage I;56;MALE;Alive;4.93;NA;2;DiseaseFree;4.93;4;30
TCGA-56-8201;Lung Squamous Cell Carcinoma;;;NA;;Cluster 14 (HNSC);;MX;T3;N0;stage II;74;MALE;Dead;13.04;NA;28;NA;NA;4;NA
TCGA-56-8304;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T1;N0;stage I;73;FEMALE;Alive;3.48;NA;106;DiseaseFree;3.48;2;58
TCGA-56-8305;Lung Squamous Cell Carcinoma;;;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;72;MALE;Alive;3.45;NA;105;DiseaseFree;3.45;3;100
TCGA-56-8307;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N0;stage II;55;FEMALE;Alive;26.87;NA;27;DiseaseFree;26.87;2;35
TCGA-56-8308;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;MX;T3;N0;stage II;79;MALE;Alive;16.98;NA;217;DiseaseFree;16.98;3;63
TCGA-56-8309;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T1;N0;stage I;66;MALE;Alive;14.06;NA;18;DiseaseFree;14.06;2;50
TCGA-56-8503;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;76;FEMALE;Alive;1.35;NA;41;DiseaseFree;1.35;2;91
TCGA-56-8504;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;74;MALE;Alive;16.75;NA;178;DiseaseFree;16.75;4;NA
TCGA-56-8622;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;68;MALE;Alive;1.81;NA;55;DiseaseFree;1.81;3;40
TCGA-56-8623;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;71;MALE;Dead;22.73;NA;6;Recurred/Progressed;21.19;2;45
TCGA-56-8624;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N0;stage II;84;MALE;Alive;13.8;NA;36;DiseaseFree;13.8;3;20
TCGA-56-8625;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N1;stage III;66;FEMALE;Dead;10.35;NA;63;Recurred/Progressed;8.94;2;NA
TCGA-56-8626;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;59;MALE;Dead;9.92;NA;17;NA;NA;2;50
TCGA-56-8628;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;78;MALE;Alive;20.24;NA;16;DiseaseFree;20.24;4;NA
TCGA-56-8629;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;63;MALE;Alive;15.8;NA;34;DiseaseFree;15.8;4;66
TCGA-56-A49D;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N2;stage III;67;MALE;Alive;20.93;NA;38;DiseaseFree;20.93;4;53
TCGA-56-A4BW;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;55;MALE;Alive;19.22;NA;2;DiseaseFree;19.22;4;120
TCGA-56-A4BX;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;70;MALE;Alive;13.3;NA;46;DiseaseFree;13.3;4;83
TCGA-56-A4BY;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;66;MALE;Dead;17.84;NA;31;NA;NA;4;65
TCGA-56-A4ZJ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;75;FEMALE;Alive;21.02;NA;25;DiseaseFree;21.02;4;100
TCGA-56-A4ZK;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;76;FEMALE;Alive;18.73;NA;4;DiseaseFree;18.73;4;NA
TCGA-56-A5DR;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;81;MALE;Alive;0.13;NA;4;DiseaseFree;0.13;1;NA
TCGA-56-A5DS;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;72;FEMALE;Alive;0.26;NA;8;DiseaseFree;0.26;2;50
TCGA-56-A62T;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;78;MALE;Alive;14.45;NA;5;DiseaseFree;14.45;2;102
TCGA-58-8386;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M1;T3;NX;stage IV;75;MALE;Dead;0.03;1;NA;NA;NA;2;65
TCGA-58-8387;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N0;stage II;60;MALE;Dead;13.24;403;NA;NA;NA;4;40
TCGA-58-8388;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;Cluster 5;;M0;T2;N0;stage I;60;MALE;Dead;13.53;NA;378;NA;NA;2;80
TCGA-58-8390;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N0;stage II;70;MALE;Alive;29.93;NA;272;DiseaseFree;29.93;4;120
TCGA-58-8391;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N2;stage III;57;FEMALE;Alive;71.19;NA;1342;Recurred/Progressed;66.79;2;30
TCGA-58-8392;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;70;MALE;Dead;16.46;501;NA;Recurred/Progressed;3.15;2;80
TCGA-58-8393;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;68;FEMALE;Alive;34.76;NA;20;DiseaseFree;34.76;2;7
TCGA-58-A46J;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;64;MALE;Alive;85.05;NA;1973;DiseaseFree;85.05;2;NA
TCGA-58-A46K;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T2;N2;stage III;59;MALE;Dead;34.33;1045;NA;Recurred/Progressed;24.15;4;10
TCGA-58-A46L;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T2;N2;stage III;73;MALE;Alive;56.6;NA;1113;DiseaseFree;56.6;5;NA
TCGA-58-A46M;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;61;MALE;Alive;35.22;NA;707;DiseaseFree;35.22;2;NA
TCGA-58-A46N;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T2;N0;stage I;52;MALE;Alive;29.89;NA;540;Recurred/Progressed;20.7;2;50
TCGA-60-2695;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;C1-LUAD-enriched;Cluster 5;RNA cluster 12;M0;T2;N0;stage I;74;FEMALE;Alive;21.09;NA;474;DiseaseFree;21.09;3;64
TCGA-60-2696;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage II;76;FEMALE;Dead;3.58;109;109;NA;NA;3;15
TCGA-60-2697;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;M0;T2;N2;stage II;41;MALE;Dead;12.22;372;NA;Recurred/Progressed;6.57;NA;NA
TCGA-60-2698;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;62;MALE;Dead;10.22;311;NA;Recurred/Progressed;3.75;4;NA
TCGA-60-2703;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;73;MALE;Dead;96.75;2945;NA;Recurred/Progressed;57.72;4;50
TCGA-60-2704;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;73;MALE;Dead;37.91;1154;NA;Recurred/Progressed;34.33;2;60
TCGA-60-2706;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;58;MALE;Alive;92.64;NA;2500;DiseaseFree;92.64;2;51
TCGA-60-2707;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;70;MALE;Dead;21.91;667;NA;Recurred/Progressed;19.02;3;49
TCGA-60-2708;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;64;FEMALE;Alive;80.39;NA;2083;DiseaseFree;80.39;4;20
TCGA-60-2709;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;MX;T2;N0;stage I;69;MALE;Alive;49.44;NA;1505;DiseaseFree;49.44;2;157.5
TCGA-60-2710;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N1;stage II;67;FEMALE;Alive;66.49;NA;1686;DiseaseFree;66.49;4;63
TCGA-60-2711;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;64;FEMALE;Alive;41.39;NA;889;DiseaseFree;41.39;4;39
TCGA-60-2712;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;79;FEMALE;Dead;9;274;274;NA;NA;3;10
TCGA-60-2713;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N0;stage I;64;MALE;Alive;56.87;NA;1456;Recurred/Progressed;47.08;2;110
TCGA-60-2714;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;66;FEMALE;Alive;50.3;NA;512;DiseaseFree;50.3;4;90
TCGA-60-2715;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T1;N0;stage I;51;MALE;Dead;35.32;1075;NA;NA;NA;4;25
TCGA-60-2716;Lung Squamous Cell Carcinoma;Lung Papillary Squamous Cell Caricnoma;;NA;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N1;stage II;39;MALE;Alive;48.46;NA;1181;DiseaseFree;48.46;1;NA
TCGA-60-2719;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;83;FEMALE;Alive;42.61;NA;932;DiseaseFree;42.61;3;7
TCGA-60-2720;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;60;FEMALE;Alive;3.19;NA;97;DiseaseFree;3.19;4;110
TCGA-60-2721;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;73;MALE;Alive;32.29;NA;794;DiseaseFree;32.29;4;93
TCGA-60-2722;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;BRCA CIMP c7;squamous-like c4;M0;T2;N1;stage II;66;MALE;Alive;29.83;NA;733;Recurred/Progressed;27.96;4;90
TCGA-60-2723;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;74;FEMALE;Alive;35.87;NA;693;DiseaseFree;35.87;4;58
TCGA-60-2724;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N1;stage III;47;MALE;Alive;23.55;NA;37;DiseaseFree;23.55;4;60
TCGA-60-2725;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;74;MALE;Alive;26.81;NA;719;DiseaseFree;26.81;3;56
TCGA-60-2726;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;56;MALE;Dead;11.76;358;358;NA;NA;4;42
TCGA-62-8394;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;;M0;T4;N2;stage III;65;FEMALE;Dead;4.57;139;NA;NA;NA;1;NA
TCGA-62-8395;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 6;;M0;T3;N0;stage II;80;FEMALE;Alive;39.95;NA;705;Recurred/Progressed;16.43;1;NA
TCGA-62-8397;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;;M0;T3;N0;stage II;70;FEMALE;Alive;42.35;NA;940;DiseaseFree;42.35;1;NA
TCGA-62-8398;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;;M0;T2;N2;stage III;55;MALE;Dead;14.59;444;NA;NA;NA;4;20
TCGA-62-8399;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;;M0;T2;N2;stage III;62;MALE;Alive;88.57;NA;2093;DiseaseFree;88.57;4;70
TCGA-62-8402;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;;M0;T2;N2;stage III;73;FEMALE;Dead;49.21;NA;1445;Recurred/Progressed;25.36;1;NA
TCGA-62-A46O;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;65;FEMALE;Dead;47.77;1454;NA;Recurred/Progressed;30.98;2;48
TCGA-62-A46P;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N0;stage I;65;MALE;Dead;19.51;594;NA;Recurred/Progressed;8.77;4;40
TCGA-62-A46R;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N0;stage I;54;FEMALE;Dead;56.67;1725;NA;NA;NA;4;25
TCGA-62-A46S;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M0;T2;N0;stage I;73;MALE;Dead;54.3;1653;NA;Recurred/Progressed;17.31;4;40
TCGA-62-A46U;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N1;stage II;71;FEMALE;Alive;67.9;NA;1708;DiseaseFree;67.9;1;NA
TCGA-62-A46V;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N0;stage I;78;FEMALE;Alive;72.24;NA;1631;DiseaseFree;72.24;3;NA
TCGA-62-A46Y;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N2;stage III;70;FEMALE;Dead;13.6;414;NA;Recurred/Progressed;10.32;1;NA
TCGA-62-A470;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;M0;T2;N0;stage I;84;MALE;Dead;39.22;1194;NA;Recurred/Progressed;17.71;3;30
TCGA-62-A471;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;64;MALE;Alive;40.93;NA;883;DiseaseFree;40.93;4;30
TCGA-62-A472;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;70;MALE;Alive;29.89;NA;540;Recurred/Progressed;9.53;2;60
TCGA-63-5128;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;NA;MALE;Dead;NA;NA;NA;NA;NA;4;NA
TCGA-63-5131;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;NA;MALE;Dead;NA;NA;NA;NA;NA;4;50
TCGA-63-6202;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage II;NA;MALE;Alive;52.63;NA;NA;DiseaseFree;52.63;4;35
TCGA-63-7020;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;NA;MALE;Alive;70.07;NA;NA;DiseaseFree;70.07;4;50
TCGA-63-7021;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T1;N0;stage I;NA;MALE;Alive;70.37;NA;NA;Recurred/Progressed;49.38;4;21
TCGA-63-7022;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T1;N0;stage I;NA;FEMALE;Alive;68.1;NA;NA;DiseaseFree;68.1;4;30
TCGA-63-7023;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N1;stage II;NA;MALE;Alive;55.26;NA;NA;DiseaseFree;55.26;4;55
TCGA-63-A5M9;Lung Squamous Cell Carcinoma;;;NA;;;;M0;T2;N1;stage II;NA;FEMALE;Alive;0;NA;0;DiseaseFree;0;4;25
TCGA-63-A5MB;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;62;MALE;Alive;102.6;NA;2758;DiseaseFree;102.6;3;25
TCGA-63-A5MG;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;68;MALE;Alive;70.57;NA;1769;DiseaseFree;70.57;3;NA
TCGA-63-A5MH;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;68;MALE;Alive;66.56;NA;1772;DiseaseFree;66.56;5;35
TCGA-63-A5MI;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N2;stage III;65;MALE;Alive;58.61;NA;1399;DiseaseFree;58.61;4;50
TCGA-63-A5MJ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;54;MALE;Alive;59.92;NA;1524;DiseaseFree;59.92;2;NA
TCGA-63-A5ML;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;68;MALE;Alive;45.53;NA;1163;DiseaseFree;45.53;4;60
TCGA-63-A5MM;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;69;FEMALE;Dead;14.98;456;NA;Recurred/Progressed;7.16;3;30
TCGA-63-A5MN;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;78;FEMALE;Dead;11.33;345;NA;Recurred/Progressed;10.51;1;NA
TCGA-63-A5MP;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;56;MALE;Alive;25.26;NA;769;Recurred/Progressed;16.79;4;41
TCGA-63-A5MR;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;70;FEMALE;Alive;89.22;NA;2367;DiseaseFree;89.22;4;120
TCGA-63-A5MS;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;78;MALE;Alive;78.22;NA;2025;DiseaseFree;78.22;3;6
TCGA-63-A5MT;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;74;MALE;Alive;16.36;NA;498;Recurred/Progressed;14.03;4;100
TCGA-63-A5MU;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;48;MALE;Dead;NA;NA;NA;Recurred/Progressed;13.8;4;15
TCGA-63-A5MV;Lung Squamous Cell Carcinoma;Lung Clear Cell Squamous Cell Carcinoma;;NA;;;;M0;T2;N0;stage II;69;MALE;Alive;36.14;NA;787;DiseaseFree;36.14;4;50
TCGA-63-A5MW;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;76;MALE;Alive;53.84;NA;140;DiseaseFree;53.84;4;60
TCGA-63-A5MY;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;63;MALE;Alive;34.56;NA;6;DiseaseFree;34.56;4;40
TCGA-64-1676;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;58;MALE;Alive;56.77;NA;1728;DiseaseFree;56.77;2;60
TCGA-64-1677;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;77;FEMALE;Dead;20.63;628;NA;Recurred/Progressed;11.83;2;50
TCGA-64-1678;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage II;70;FEMALE;Alive;39.06;NA;1189;DiseaseFree;39.06;3;20
TCGA-64-1679;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C2-Squamous-like;Low purity c2;LUAD-like c10;M0;T1;N2;stage III;58;FEMALE;Alive;81.73;NA;1686;DiseaseFree;81.73;2;40
TCGA-64-1680;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T2;N2;stage IV;63;MALE;Alive;36.99;NA;1126;DiseaseFree;36.99;3;50
TCGA-64-1681;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;61;FEMALE;Dead;38.34;1167;NA;Recurred/Progressed;14.42;3;NA
TCGA-64-5774;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;60;MALE;Alive;87.91;NA;2550;Recurred/Progressed;9.1;4;45
TCGA-64-5775;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C12-small-various;Cluster 6;RNA cluster 2;M0;T4;N0;stage III;71;MALE;Dead;2.04;62;NA;NA;NA;2;110
TCGA-64-5778;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;60;MALE;Alive;42.87;NA;926;Recurred/Progressed;38.37;4;68
TCGA-64-5779;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;61;MALE;Alive;28.38;NA;507;Recurred/Progressed;26.12;4;40
TCGA-64-5781;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;55;FEMALE;Alive;51.22;NA;1202;Recurred/Progressed;3.15;4;25
TCGA-64-5815;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;74;MALE;Alive;28.45;NA;224;DiseaseFree;28.45;3;30
TCGA-66-2727;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;55;FEMALE;Dead;16.95;516;NA;NA;NA;4;56
TCGA-66-2734;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;62;FEMALE;Alive;43.07;NA;1311;DiseaseFree;43.07;4;40
TCGA-66-2737;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;72;MALE;Alive;2;NA;61;DiseaseFree;2;3;40
TCGA-66-2742;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M1;T2;N1;stage IV;70;MALE;Alive;21.06;NA;641;DiseaseFree;21.06;3;44
TCGA-66-2744;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;71;MALE;Alive;0.99;NA;30;DiseaseFree;0.99;4;63
TCGA-66-2753;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;69;MALE;Alive;1.02;NA;31;DiseaseFree;1.02;4;162
TCGA-66-2754;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;67;MALE;Alive;2;NA;61;DiseaseFree;2;4;40
TCGA-66-2755;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;63;MALE;Alive;0.92;NA;28;DiseaseFree;0.92;3;20
TCGA-66-2756;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T4;N0;stage III;68;MALE;Alive;0.99;NA;30;DiseaseFree;0.99;4;NA
TCGA-66-2757;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;Cluster 5;RNA cluster 12;M0;T1;N0;stage I;65;FEMALE;Dead;43.96;NA;30;Recurred/Progressed;29.96;4;72
TCGA-66-2758;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;71;MALE;Alive;20.99;NA;639;DiseaseFree;20.99;4;56
TCGA-66-2759;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N2;stage III;66;MALE;Alive;25.03;NA;762;DiseaseFree;25.03;3;16
TCGA-66-2763;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;63;FEMALE;Alive;0.99;NA;30;DiseaseFree;0.99;4;40
TCGA-66-2765;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;64;MALE;Alive;2;NA;61;DiseaseFree;2;4;108
TCGA-66-2766;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N2;stage III;54;MALE;Alive;1.02;NA;31;DiseaseFree;1.02;4;80
TCGA-66-2767;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N3;stage III;62;MALE;Alive;2;NA;61;DiseaseFree;2;4;43
TCGA-66-2768;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;57;MALE;Alive;2;NA;61;DiseaseFree;2;2;NA
TCGA-66-2769;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T4;N0;stage III;75;MALE;Dead;7.06;215;NA;NA;NA;3;33
TCGA-66-2770;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;79;MALE;Alive;23;NA;700;DiseaseFree;23;3;25
TCGA-66-2771;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N1;stage II;60;MALE;Alive;18.99;NA;578;DiseaseFree;18.99;4;70
TCGA-66-2773;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;69;MALE;Dead;3.02;92;NA;NA;NA;3;58
TCGA-66-2777;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;OV-like c1;squamous-like c4;M0;T2;N0;stage I;71;MALE;Alive;2;NA;61;DiseaseFree;2;4;12
TCGA-66-2778;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N3;stage III;68;FEMALE;Alive;18.99;NA;578;DiseaseFree;18.99;4;37
TCGA-66-2780;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;65;MALE;Dead;12.02;366;NA;NA;NA;3;28
TCGA-66-2781;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N0;stage I;67;MALE;Alive;3.98;NA;121;DiseaseFree;3.98;4;80
TCGA-66-2782;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N0;stage II;71;MALE;Dead;11.99;365;NA;Recurred/Progressed;9.99;4;50
TCGA-66-2783;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N3;stage III;67;MALE;Alive;24.93;NA;759;DiseaseFree;24.93;4;65
TCGA-66-2785;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C4-BRCA/Basal;Cluster 5;BRCA basal-like c8;M0;T2;N0;stage I;65;MALE;Alive;1.97;NA;60;DiseaseFree;1.97;4;70
TCGA-66-2786;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T1;N0;stage I;68;FEMALE;Alive;25.95;NA;790;DiseaseFree;25.95;4;74
TCGA-66-2787;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;57;MALE;Alive;39.98;NA;1217;DiseaseFree;39.98;4;40
TCGA-66-2788;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;basal;C2-Squamous-like;Low purity c2;squamous-like c4;M0;T2;N0;stage I;56;MALE;Alive;22.96;NA;699;DiseaseFree;22.96;4;80
TCGA-66-2789;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N3;stage III;73;MALE;Dead;4.04;123;NA;NA;NA;4;40
TCGA-66-2790;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;72;MALE;Alive;22.96;NA;699;Recurred/Progressed;22.96;4;57
TCGA-66-2791;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N3;stage III;66;MALE;Dead;5.03;153;NA;NA;NA;4;25
TCGA-66-2792;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;58;MALE;Alive;29.99;NA;913;DiseaseFree;29.99;4;10
TCGA-66-2793;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T4;N1;stage III;68;MALE;Dead;10.05;306;NA;NA;NA;4;112
TCGA-66-2794;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T4;N2;stage III;64;MALE;Alive;54.04;NA;1645;DiseaseFree;54.04;4;100
TCGA-66-2795;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T4;N1;stage III;68;MALE;Alive;4.01;NA;122;DiseaseFree;4.01;4;86
TCGA-66-2800;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T4;N0;stage III;70;MALE;Alive;49.01;NA;1492;DiseaseFree;49.01;4;75
TCGA-67-3770;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;LUAD-like c10;M0;T1;N0;stage I;70;FEMALE;Alive;20.04;NA;610;DiseaseFree;20.04;3;NA
TCGA-67-3771;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;OV-like c1;LUAD-like c10;M0;T1;N0;stage I;77;FEMALE;Alive;20.04;NA;610;DiseaseFree;20.04;4;NA
TCGA-67-3772;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T2;N0;stage I;82;FEMALE;Alive;18.82;NA;573;DiseaseFree;18.82;1;NA
TCGA-67-3773;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;84;FEMALE;Alive;14.03;NA;427;DiseaseFree;14.03;3;NA
TCGA-67-3774;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;73;FEMALE;Alive;12.65;NA;385;DiseaseFree;12.65;3;NA
TCGA-67-4679;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N0;;69;MALE;Alive;14.72;NA;448;DiseaseFree;14.72;4;NA
TCGA-67-6215;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;52;FEMALE;Alive;5.72;NA;162;DiseaseFree;5.72;1;NA
TCGA-67-6216;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;57;FEMALE;Alive;4.63;NA;141;DiseaseFree;4.63;1;NA
TCGA-67-6217;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;73;FEMALE;Alive;13.86;NA;422;Recurred/Progressed;9.72;3;NA
TCGA-68-7755;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N1;stage II;60;FEMALE;Alive;2.73;NA;83;DiseaseFree;2.73;4;78
TCGA-68-7756;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T4;N1;stage III;84;MALE;Alive;6.64;NA;202;DiseaseFree;6.64;3;20
TCGA-68-7757;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T1;N0;stage I;74;MALE;Alive;6.93;NA;211;DiseaseFree;6.93;4;25
TCGA-68-8250;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T1;N0;stage I;66;MALE;Alive;8.02;NA;244;DiseaseFree;8.02;4;50
TCGA-68-8251;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;78;MALE;Alive;13.34;NA;96;DiseaseFree;13.34;3;52
TCGA-68-A59I;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N1;stage III;73;FEMALE;Alive;16.16;NA;121;Recurred/Progressed;5.22;4;50
TCGA-68-A59J;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;74;FEMALE;Alive;14.72;NA;104;DiseaseFree;14.72;4;45
TCGA-69-7760;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N0;stage II;73;MALE;Alive;6.64;NA;154;DiseaseFree;6.64;1;NA
TCGA-69-7761;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;84;MALE;Alive;6.11;NA;186;DiseaseFree;6.11;3;20
TCGA-69-7763;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;69;MALE;Alive;22.67;NA;690;DiseaseFree;22.67;4;7.5
TCGA-69-7764;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;75;MALE;Alive;13.6;NA;414;DiseaseFree;13.6;3;30
TCGA-69-7765;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T4;N0;stage IV;56;MALE;Alive;5.42;NA;129;DiseaseFree;5.42;4;NA
TCGA-69-7973;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;42;FEMALE;Alive;7.56;NA;230;DiseaseFree;7.56;4;25
TCGA-69-7974;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 6;LUAD-like c10;MX;T2;N2;stage III;54;FEMALE;Alive;6.04;NA;184;DiseaseFree;6.04;4;30
TCGA-69-7978;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 6;LUAD-like c10;MX;T2;N1;stage II;59;MALE;Alive;4.4;NA;70;DiseaseFree;4.4;2;80
TCGA-69-7979;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;71;FEMALE;Alive;13.4;NA;89;DiseaseFree;13.4;2;28
TCGA-69-7980;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;70;FEMALE;Alive;13.5;NA;43;DiseaseFree;13.5;4;80
TCGA-69-8253;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;LUAD-like c10;MX;T1;N1;stage II;59;FEMALE;Alive;13.99;NA;100;DiseaseFree;13.99;4;7.8
TCGA-69-8254;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 6;LUAD-like c10;;T2;;;85;MALE;Alive;13.44;NA;77;DiseaseFree;13.44;3;40
TCGA-69-8255;Lung Adenocarcinoma;Lung Solid Pattern Predominant Adenocarcinoma;;NA;;Cluster 5;LAML-like c13;M0;T1;N0;stage I;71;MALE;Alive;4.24;NA;129;DiseaseFree;4.24;2;40
TCGA-69-8453;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;;NA;;Cluster 5;;MX;T3;N0;stage II;77;MALE;Alive;26.71;NA;171;Recurred/Progressed;11.3;3;12
TCGA-69-A59K;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T3;N0;stage II;60;FEMALE;Alive;19.42;NA;214;DiseaseFree;19.42;4;25
TCGA-6A-AB49;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;73;FEMALE;Dead;NA;NA;NA;NA;NA;3;50
TCGA-70-6722;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N1;stage III;47;MALE;Alive;12.06;NA;0;Recurred/Progressed;9.63;1;NA
TCGA-70-6723;Lung Squamous Cell Carcinoma;Lung Papillary Squamous Cell Caricnoma;;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N0;stage II;65;MALE;Alive;12.32;NA;0;Recurred/Progressed;10.25;1;NA
TCGA-71-6725;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;48;FEMALE;Alive;8.41;NA;61;Recurred/Progressed;5.39;2;NA
TCGA-71-8520;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;60;FEMALE;Dead;6.9;NA;3;Recurred/Progressed;5.88;1;NA
TCGA-73-4658;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;80;FEMALE;Dead;52.56;1600;1600;NA;NA;3;25
TCGA-73-4659;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;66;MALE;Dead;23.36;711;711;Recurred/Progressed;10.38;3;12
TCGA-73-4662;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;65;FEMALE;Alive;82.62;NA;912;Recurred/Progressed;0.69;3;10
TCGA-73-4666;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T1;N0;stage IV;52;FEMALE;Alive;26.28;NA;618;DiseaseFree;26.28;4;10
TCGA-73-4668;Lung Adenocarcinoma;Lung Micropapillary Adenocarcinoma;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;66;FEMALE;Alive;15.34;NA;467;Recurred/Progressed;9.26;4;55
TCGA-73-4670;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T2;N0;stage IV;69;FEMALE;Alive;4.3;NA;14;DiseaseFree;4.3;4;30
TCGA-73-4675;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N1;stage III;59;MALE;Dead;30.29;NA;40;Recurred/Progressed;11.86;4;41
TCGA-73-4676;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;45;MALE;Dead;9.23;NA;122;NA;NA;4;48
TCGA-73-4677;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;74;MALE;Dead;1.25;38;NA;NA;NA;3;NA
TCGA-73-7498;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;58;FEMALE;Alive;39.06;NA;621;DiseaseFree;39.06;4;28
TCGA-73-7499;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;81;FEMALE;Dead;50.3;NA;519;Recurred/Progressed;47.54;1;NA
TCGA-73-A9RS;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;41;MALE;Dead;11.17;NA;305;Recurred/Progressed;3.52;2;11
TCGA-75-5122;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;NA;MALE;Dead;NA;NA;NA;NA;NA;3;20
TCGA-75-5125;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;NA;MALE;Dead;66.59;NA;NA;Recurred/Progressed;57.56;3;25
TCGA-75-5126;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N2;stage III;NA;FEMALE;Alive;NA;NA;NA;DiseaseFree;NA;4;40
TCGA-75-5146;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;NA;MALE;Alive;77.79;NA;NA;Recurred/Progressed;58.25;3;NA
TCGA-75-5147;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;NA;FEMALE;Alive;43.79;NA;NA;DiseaseFree;43.79;1;NA
TCGA-75-6203;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T2;N2;stage III;NA;FEMALE;Alive;NA;NA;NA;DiseaseFree;NA;1;0
TCGA-75-6205;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;NA;FEMALE;Dead;NA;NA;NA;NA;NA;1;NA
TCGA-75-6206;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;;LUAD-like c10;M0;T2;N0;stage I;NA;MALE;Alive;85.09;NA;NA;DiseaseFree;85.09;3;20
TCGA-75-6207;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;NA;MALE;Dead;NA;NA;NA;NA;NA;3;10
TCGA-75-6211;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;NA;FEMALE;Dead;NA;NA;NA;NA;NA;2;34
TCGA-75-6212;Lung Adenocarcinoma;Lung Micropapillary Adenocarcinoma;Bronchioid;NA;C1-LUAD-enriched;KIRC-like c17;LUAD-like c10;M0;T2;N1;stage II;NA;FEMALE;Dead;49.8;NA;NA;Recurred/Progressed;44.02;1;NA
TCGA-75-6214;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N2;stage III;NA;FEMALE;Dead;36.63;NA;NA;Recurred/Progressed;13.76;2;40
TCGA-75-7025;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;NA;MALE;Alive;108.57;NA;NA;Recurred/Progressed;48.65;3;NA
TCGA-75-7027;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;NA;MALE;Alive;100.49;NA;NA;Recurred/Progressed;96.88;2;50
TCGA-75-7030;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T3;N0;stage II;NA;MALE;Alive;NA;NA;NA;DiseaseFree;NA;1;NA
TCGA-75-7031;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C4-BRCA/Basal;Low purity c2;LUAD-like c10;M0;T2;N0;stage I;NA;FEMALE;Alive;NA;NA;NA;DiseaseFree;NA;3;5
TCGA-77-6842;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N1;stage II;79;MALE;Dead;29.53;899;NA;Recurred/Progressed;6.6;4;22.5
TCGA-77-6843;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N1;stage II;74;MALE;Dead;73.06;2224;NA;NA;NA;2;30
TCGA-77-6844;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N1;stage III;74;MALE;Dead;75.03;2284;NA;Recurred/Progressed;58.74;4;45
TCGA-77-6845;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N0;stage II;69;MALE;Dead;23.26;708;NA;NA;NA;4;51
TCGA-77-7138;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;squamous-like c4;M0;T2;N0;stage I;67;MALE;Dead;11.17;340;NA;NA;NA;3;20
TCGA-77-7139;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;56;MALE;Alive;139.98;NA;2737;DiseaseFree;139.98;4;2
TCGA-77-7140;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;69;FEMALE;Dead;20.76;632;NA;Recurred/Progressed;8.21;1;NA
TCGA-77-7141;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;BRCA CIMP c7;squamous-like c4;M0;T2;N0;stage I;64;MALE;Alive;0.49;NA;15;DiseaseFree;0.49;4;70
TCGA-77-7142;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;59;FEMALE;Alive;73.16;NA;1286;DiseaseFree;73.16;4;52.5
TCGA-77-7335;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T4;N2;stage III;62;FEMALE;Dead;70.07;2133;NA;NA;NA;3;52
TCGA-77-7337;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;65;MALE;Dead;106.87;3253;NA;NA;NA;4;79.5
TCGA-77-7338;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;64;MALE;Dead;0.16;5;NA;NA;NA;2;41.25
TCGA-77-7463;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;75;MALE;Dead;46.75;1423;NA;NA;NA;4;42
TCGA-77-7465;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N1;stage II;58;MALE;Alive;32.52;NA;479;DiseaseFree;32.52;2;120
TCGA-77-8007;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;68;MALE;Dead;6.5;198;NA;Recurred/Progressed;4.57;2;100
TCGA-77-8008;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;squamous-like c4;M0;T2;N0;stage I;68;MALE;Dead;86.7;2639;NA;NA;NA;4;61.5
TCGA-77-8009;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;BRCA CIMP c7;squamous-like c4;M0;T2;N1;stage II;68;MALE;Dead;55.68;NA;1641;Recurred/Progressed;19.94;4;97.5
TCGA-77-8128;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N2;stage III;60;MALE;Dead;37.78;1150;NA;NA;NA;2;113
TCGA-77-8130;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N1;stage II;69;MALE;Alive;156.54;NA;2522;Recurred/Progressed;146.88;4;32.25
TCGA-77-8131;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;M0;T2;NX;stage I;72;MALE;Dead;12.58;383;NA;NA;NA;4;69
TCGA-77-8133;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N1;stage II;74;MALE;Dead;53.88;1640;NA;NA;NA;2;22
TCGA-77-8136;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N1;stage II;74;FEMALE;Dead;39.06;1189;NA;Recurred/Progressed;9.89;2;135
TCGA-77-8138;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N0;stage I;74;MALE;Dead;17.71;539;NA;Recurred/Progressed;9.49;4;54
TCGA-77-8139;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N0;stage II;72;MALE;Alive;104.01;NA;3166;DiseaseFree;104.01;2;52
TCGA-77-8140;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N1;stage II;66;FEMALE;Dead;11.53;351;NA;NA;NA;4;78
TCGA-77-8143;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T2;N2;stage III;76;MALE;Dead;26.38;803;NA;NA;NA;4;30
TCGA-77-8144;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;70;MALE;Alive;27.37;NA;833;DiseaseFree;27.37;2;59
TCGA-77-8145;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T4;N1;stage III;73;MALE;Dead;6.96;212;NA;Recurred/Progressed;4.47;2;57
TCGA-77-8146;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;72;MALE;Alive;104.76;NA;2183;DiseaseFree;104.76;2;75
TCGA-77-8148;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N1;stage III;68;MALE;Alive;66.46;NA;293;DiseaseFree;66.46;4;60
TCGA-77-8150;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T3;N1;stage III;64;MALE;Dead;54.37;1655;NA;Recurred/Progressed;47.83;2;46
TCGA-77-8153;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;77;FEMALE;Alive;65.44;NA;1684;DiseaseFree;65.44;3;25
TCGA-77-8154;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N0;stage I;67;MALE;Alive;60.48;NA;1092;DiseaseFree;60.48;4;40
TCGA-77-8156;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;60;MALE;Alive;36.33;NA;10;DiseaseFree;36.33;2;57.5
TCGA-77-A5FZ;Lung Squamous Cell Carcinoma;Lung Papillary Squamous Cell Caricnoma;;NA;;;;M0;T4;N0;stage III;64;MALE;Dead;126.08;3838;NA;NA;NA;4;141
TCGA-77-A5G1;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N1;stage III;75;MALE;Alive;132.26;NA;3714;Recurred/Progressed;72.17;4;53
TCGA-77-A5G3;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;63;MALE;Alive;150.13;NA;3576;DiseaseFree;150.13;4;40
TCGA-77-A5G6;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N2;stage III;66;MALE;Dead;22.27;678;NA;Recurred/Progressed;12.88;2;74
TCGA-77-A5G7;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;63;MALE;Dead;5.91;180;NA;NA;NA;2;69
TCGA-77-A5G8;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;70;MALE;Alive;61.89;NA;1290;DiseaseFree;61.89;4;90
TCGA-77-A5GA;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;76;MALE;Alive;42.05;NA;36;DiseaseFree;42.05;3;99
TCGA-77-A5GB;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;NX;stage I;90;MALE;Dead;30.78;937;NA;Recurred/Progressed;7.52;2;52
TCGA-77-A5GF;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;70;MALE;Dead;27.6;NA;722;Recurred/Progressed;23.72;4;60
TCGA-77-A5GH;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;81;MALE;Alive;38.83;NA;713;DiseaseFree;38.83;3;11
TCGA-78-7143;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;62;FEMALE;Dead;162.98;4961;NA;Recurred/Progressed;151.38;1;NA
TCGA-78-7145;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T4;N1;stage IV;52;FEMALE;Dead;27.14;826;NA;Recurred/Progressed;13.86;4;25
TCGA-78-7146;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;71;FEMALE;Dead;5.68;173;NA;NA;NA;4;6
TCGA-78-7147;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;67;FEMALE;Dead;19.25;586;NA;Recurred/Progressed;18.99;2;50
TCGA-78-7148;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;71;MALE;Dead;20.57;626;NA;Recurred/Progressed;5.98;2;57
TCGA-78-7149;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T4;N0;stage III;71;MALE;Alive;129.43;NA;1093;DiseaseFree;129.43;2;115
TCGA-78-7150;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;59;MALE;Dead;21.88;666;NA;Recurred/Progressed;4.57;4;37
TCGA-78-7152;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;65;MALE;Dead;39.91;NA;1202;Recurred/Progressed;39.49;4;40
TCGA-78-7153;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;65;FEMALE;Alive;119.42;NA;760;DiseaseFree;119.42;4;20
TCGA-78-7154;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N2;stage III;72;MALE;Dead;19.48;593;NA;NA;NA;4;112.5
TCGA-78-7155;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;RNA cluster 14;M0;T2;N0;stage I;68;MALE;Dead;38.47;1171;NA;Recurred/Progressed;6.87;4;48
TCGA-78-7156;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M1;T4;N1;stage IV;62;MALE;Dead;32.06;976;NA;NA;NA;3;84
TCGA-78-7158;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T4;N2;stage III;59;FEMALE;Dead;5.88;179;NA;Recurred/Progressed;4.34;4;14
TCGA-78-7159;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;NX;stage I;60;FEMALE;Alive;64.85;NA;1221;DiseaseFree;64.85;4;21
TCGA-78-7160;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M1;T4;N2;stage IV;61;MALE;Dead;22.9;NA;678;NA;NA;4;43.8
TCGA-78-7161;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T3;N0;stage II;69;FEMALE;Dead;9.56;NA;215;Recurred/Progressed;5.32;4;27.8
TCGA-78-7162;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;75;MALE;Dead;104.11;3169;NA;Recurred/Progressed;90.01;2;12
TCGA-78-7163;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;60;MALE;Alive;238.11;NA;6812;DiseaseFree;238.11;4;41
TCGA-78-7166;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;84;MALE;Dead;8.48;258;NA;NA;NA;3;38
TCGA-78-7167;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M1;T2;N0;stage IV;77;MALE;Dead;88.07;2681;NA;Recurred/Progressed;23.85;2;64
TCGA-78-7220;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;53;FEMALE;Dead;26.51;807;NA;Recurred/Progressed;17.44;2;35
TCGA-78-7535;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;45;MALE;Dead;31.18;949;NA;Recurred/Progressed;26.58;2;35
TCGA-78-7536;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N2;stage III;69;MALE;Dead;8.02;244;NA;Recurred/Progressed;7.59;4;44
TCGA-78-7537;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;72;MALE;Dead;53.29;1622;NA;NA;NA;3;20
TCGA-78-7539;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage II;75;FEMALE;Alive;25.99;NA;327;Recurred/Progressed;22.6;3;2.2
TCGA-78-7540;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Mucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;66;FEMALE;Dead;39.32;NA;881;NA;NA;1;NA
TCGA-78-7542;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C2-Squamous-like;Cluster 6;squamous-like c4;M0;T2;N0;stage I;56;MALE;Dead;10.55;321;NA;NA;NA;2;60
TCGA-78-7633;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;67;MALE;Dead;50.2;NA;994;Recurred/Progressed;47.63;4;94
TCGA-78-8640;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N1;stage II;59;MALE;Alive;232;NA;6346;DiseaseFree;232;2;45
TCGA-78-8648;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;58;FEMALE;Dead;39.72;1209;NA;Recurred/Progressed;23.65;2;45
TCGA-78-8655;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;77;FEMALE;Alive;77.53;NA;2360;DiseaseFree;77.53;4;10
TCGA-78-8660;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;69;MALE;Dead;10.55;321;NA;Recurred/Progressed;7.95;4;11
TCGA-78-8662;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;53;FEMALE;Dead;110.41;3361;NA;Recurred/Progressed;100;2;45
TCGA-79-5596;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N1;stage III;NA;MALE;Alive;NA;NA;NA;DiseaseFree;NA;4;40
TCGA-80-5607;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;NA;FEMALE;Alive;NA;NA;NA;DiseaseFree;NA;3;15
TCGA-80-5608;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;NA;FEMALE;Alive;93.04;NA;NA;DiseaseFree;93.04;2;26
TCGA-80-5611;Lung Adenocarcinoma;Lung Solid Pattern Predominant Adenocarcinoma;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;NA;MALE;Alive;85.25;NA;NA;DiseaseFree;85.25;4;60
TCGA-83-5908;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;59;FEMALE;Alive;27.07;NA;420;DiseaseFree;27.07;4;69
TCGA-85-6175;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;secretory;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T3;N0;stage II;63;FEMALE;Dead;9.66;NA;0;NA;NA;1;NA
TCGA-85-6560;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;primitive;C1-LUAD-enriched;BRCA CIMP c7;RNA cluster 2;M0;T1;N1;stage II;59;MALE;Alive;41.36;NA;11;DiseaseFree;41.36;4;40
TCGA-85-6561;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;classical;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;NX;stage I;66;MALE;Alive;40.21;NA;24;DiseaseFree;40.21;4;35
TCGA-85-6798;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T3;N1;stage III;57;MALE;Dead;6.41;NA;34;Recurred/Progressed;5.91;2;35
TCGA-85-7696;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N0;stage I;64;MALE;Alive;36.5;NA;18;DiseaseFree;36.5;4;30
TCGA-85-7697;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N0;stage II;49;MALE;Alive;34.92;NA;10;DiseaseFree;34.92;3;30
TCGA-85-7698;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N0;stage I;48;MALE;Alive;31.27;NA;49;Recurred/Progressed;21.35;3;44
TCGA-85-7699;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T4;N0;stage III;73;MALE;Dead;32.88;NA;1;Recurred/Progressed;24.97;3;74
TCGA-85-7710;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T1;N0;stage I;59;FEMALE;Alive;1.38;NA;0;DiseaseFree;1.38;2;45
TCGA-85-7843;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N1;stage II;50;MALE;Alive;1.15;NA;35;DiseaseFree;1.15;2;35
TCGA-85-7844;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;M0;T2;N0;stage I;71;MALE;Alive;29.93;NA;38;DiseaseFree;29.93;2;40
TCGA-85-7950;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;46;MALE;Alive;18.92;NA;60;DiseaseFree;18.92;2;27
TCGA-85-8048;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;62;MALE;Alive;25.13;NA;26;DiseaseFree;25.13;2;50
TCGA-85-8049;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;57;MALE;Alive;19.02;NA;60;DiseaseFree;19.02;1;NA
TCGA-85-8052;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N0;stage II;53;MALE;Alive;24.11;NA;16;DiseaseFree;24.11;2;40
TCGA-85-8070;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;71;MALE;Alive;31.54;NA;43;DiseaseFree;31.54;2;50
TCGA-85-8071;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N1;stage II;52;MALE;Alive;26.77;NA;14;DiseaseFree;26.77;2;30
TCGA-85-8072;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N0;stage I;60;MALE;Alive;30.62;NA;36;DiseaseFree;30.62;2;15
TCGA-85-8276;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 14 (HNSC);;M0;T1;N1;stage II;62;MALE;Alive;34.49;NA;13;Recurred/Progressed;34.43;2;20
TCGA-85-8277;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T3;N1;stage III;70;MALE;Dead;10.09;NA;11;NA;NA;1;NA
TCGA-85-8287;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;72;MALE;Dead;0.76;NA;13;NA;NA;2;50
TCGA-85-8288;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T1;N1;stage II;70;MALE;Dead;13.21;NA;54;NA;NA;2;50
TCGA-85-8350;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Low purity c2;;M0;T1;N0;stage I;61;MALE;Alive;22.44;NA;60;DiseaseFree;22.44;2;40
TCGA-85-8351;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N1;stage II;72;MALE;Alive;16.75;NA;55;DiseaseFree;16.75;2;60
TCGA-85-8352;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T3;N1;stage III;67;MALE;Dead;5.29;NA;67;Recurred/Progressed;4.2;2;50
TCGA-85-8353;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T3;N1;stage III;72;MALE;Dead;3.09;NA;54;NA;NA;2;50
TCGA-85-8354;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T2;N0;stage I;53;MALE;Alive;32.69;NA;61;DiseaseFree;32.69;2;30
TCGA-85-8355;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;63;MALE;Alive;2;NA;20;DiseaseFree;2;1;NA
TCGA-85-8479;Lung Squamous Cell Carcinoma;Lung Papillary Squamous Cell Caricnoma;;NA;;BRCA CIMP c7;;M0;T1;N0;stage I;66;MALE;Alive;15.37;NA;22;DiseaseFree;15.37;4;90
TCGA-85-8481;Lung Squamous Cell Carcinoma;Lung Papillary Squamous Cell Caricnoma;;NA;;Cluster 5;;M0;T3;N0;stage II;70;MALE;Dead;7.75;NA;21;NA;NA;4;80
TCGA-85-8580;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;52;FEMALE;Alive;36.56;NA;28;DiseaseFree;36.56;4;38
TCGA-85-8582;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;49;MALE;Alive;38.11;NA;4;DiseaseFree;38.11;2;40
TCGA-85-8584;Lung Squamous Cell Carcinoma;Lung Papillary Squamous Cell Caricnoma;;NA;;;;M0;T2;N1;stage II;71;MALE;Dead;12.58;NA;0;NA;NA;2;50
TCGA-85-8664;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;73;MALE;Dead;18.07;NA;3;Recurred/Progressed;14.26;2;60
TCGA-85-8666;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;65;MALE;Dead;22.57;NA;14;NA;NA;2;55
TCGA-85-A4CL;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;65;MALE;Dead;30.26;NA;15;NA;NA;2;40
TCGA-85-A4CN;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;56;FEMALE;Alive;34.1;NA;6;DiseaseFree;34.1;4;NA
TCGA-85-A4JB;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;74;MALE;Alive;30.95;NA;-10;DiseaseFree;30.95;2;25
TCGA-85-A4JC;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;84;MALE;Dead;19.84;NA;-10;Recurred/Progressed;18;2;25
TCGA-85-A4PA;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;61;MALE;Alive;24.34;NA;-6;DiseaseFree;24.34;4;40
TCGA-85-A4QQ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;68;MALE;Dead;30.45;NA;-2;NA;NA;2;50
TCGA-85-A4QR;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;67;MALE;Alive;19.71;NA;25;DiseaseFree;19.71;4;50
TCGA-85-A50M;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;47;MALE;Dead;27.14;NA;19;NA;NA;4;15
TCGA-85-A50Z;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;57;MALE;Alive;16.2;NA;0;Recurred/Progressed;15.18;2;45
TCGA-85-A510;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;74;FEMALE;Alive;15.83;NA;0;Recurred/Progressed;11.93;2;45
TCGA-85-A511;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;62;MALE;Dead;14.95;NA;0;Recurred/Progressed;12.81;2;40
TCGA-85-A512;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N1;stage II;46;MALE;Alive;15.28;NA;0;DiseaseFree;15.28;2;25
TCGA-85-A513;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;NX;stage I;60;FEMALE;Alive;29.89;NA;24;DiseaseFree;29.89;1;NA
TCGA-85-A53L;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;63;MALE;Alive;12.39;NA;13;DiseaseFree;12.39;4;30
TCGA-85-A5B5;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;58;MALE;Alive;3.65;NA;111;DiseaseFree;3.65;4;15
TCGA-86-6562;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;52;MALE;Dead;12.35;NA;0;Recurred/Progressed;9;1;NA
TCGA-86-6851;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N1;stage II;73;FEMALE;Alive;5.88;NA;0;DiseaseFree;5.88;2;52
TCGA-86-7701;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M1;T2;N0;stage IV;66;MALE;Alive;31.11;NA;11;Recurred/Progressed;29.57;1;0
TCGA-86-7711;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;70;MALE;Dead;34.36;NA;27;NA;NA;2;50
TCGA-86-7713;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage II;70;MALE;Alive;38.01;NA;7;DiseaseFree;38.01;1;NA
TCGA-86-7714;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;;Cluster 6;LUAD-like c10;M0;T1;N2;stage III;61;FEMALE;Dead;20.53;NA;0;NA;NA;2;43
TCGA-86-7953;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;69;FEMALE;Alive;32.75;NA;34;DiseaseFree;32.75;1;NA
TCGA-86-7954;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;68;FEMALE;Alive;19.88;NA;0;DiseaseFree;19.88;3;8
TCGA-86-7955;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;62;MALE;Alive;35.22;NA;14;Recurred/Progressed;26.94;1;NA
TCGA-86-8054;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;61;MALE;Alive;37.71;NA;19;DiseaseFree;37.71;2;9
TCGA-86-8055;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;79;MALE;Dead;4.07;NA;10;NA;NA;2;60
TCGA-86-8056;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 6;LUAD-like c10;M0;T4;N0;stage III;63;FEMALE;Alive;4.57;NA;0;DiseaseFree;4.57;3;36
TCGA-86-8073;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;58;MALE;Alive;24.31;NA;13;DiseaseFree;24.31;2;40
TCGA-86-8074;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T1;N1;stage II;62;FEMALE;Alive;0.79;NA;24;DiseaseFree;0.79;2;40
TCGA-86-8075;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;66;FEMALE;Dead;22.8;NA;43;Recurred/Progressed;6.54;1;NA
TCGA-86-8076;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;42;MALE;Alive;32.62;NA;26;DiseaseFree;32.62;1;NA
TCGA-86-8278;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;;M0;T2;N1;stage II;63;FEMALE;Alive;31.01;NA;23;Recurred/Progressed;0.95;1;NA
TCGA-86-8279;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T2;N1;stage II;46;MALE;Alive;31.18;NA;21;DiseaseFree;31.18;1;NA
TCGA-86-8280;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;Cluster 5;LUAD-like c10;M0;T2;N0;stage II;54;FEMALE;Alive;23.03;NA;16;DiseaseFree;23.03;1;NA
TCGA-86-8281;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;NX;stage I;75;MALE;Alive;0;NA;0;DiseaseFree;0;3;30
TCGA-86-8358;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;;M0;T2;N0;stage I;44;MALE;Alive;21.45;NA;19;DiseaseFree;21.45;2;20
TCGA-86-8359;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N2;stage III;52;MALE;Dead;14.59;NA;26;NA;NA;2;36
TCGA-86-8585;Lung Adenocarcinoma;Lung Solid Pattern Predominant Adenocarcinoma;;NA;;;;M0;T2;N0;stage I;57;MALE;Alive;11.6;NA;35;DiseaseFree;11.6;1;NA
TCGA-86-8668;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Mucinous;;NA;;;;M0;T1;N0;stage I;61;FEMALE;Alive;13.9;NA;45;DiseaseFree;13.9;1;NA
TCGA-86-8669;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;64;MALE;Alive;30.81;NA;34;Recurred/Progressed;27.89;2;47
TCGA-86-8671;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M0;T2;N1;stage II;72;FEMALE;Alive;27.56;NA;18;DiseaseFree;27.56;1;NA
TCGA-86-8672;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;59;MALE;Dead;0.62;NA;15;NA;NA;1;NA
TCGA-86-8673;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;;;M0;T2;N0;stage I;61;MALE;Alive;28.32;NA;0;Recurred/Progressed;20.89;2;54
TCGA-86-8674;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M0;T2;N1;stage II;50;MALE;Alive;26.48;NA;0;Recurred/Progressed;10.97;4;37.5
TCGA-86-A456;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M0;T1;N0;stage I;78;FEMALE;Alive;29.43;NA;10;DiseaseFree;29.43;4;NA
TCGA-86-A4D0;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;48;MALE;Dead;3.81;NA;30;NA;NA;2;NA
TCGA-86-A4JF;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;56;MALE;Dead;24.21;NA;0;Recurred/Progressed;14.32;4;NA
TCGA-86-A4P7;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;63;FEMALE;Alive;13.63;NA;14;DiseaseFree;13.63;1;NA
TCGA-86-A4P8;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N2;stage III;59;FEMALE;Alive;26.45;NA;39;DiseaseFree;26.45;1;NA
TCGA-90-6837;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Low purity c2;squamous-like c4;MX;T3;N0;stage II;64;MALE;Alive;24.9;NA;42;DiseaseFree;24.9;4;40
TCGA-90-7766;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T1;N0;stage I;66;FEMALE;Alive;9.49;NA;47;Recurred/Progressed;9.49;2;30
TCGA-90-7767;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;MX;T2;N1;stage II;56;MALE;Alive;2.92;NA;89;DiseaseFree;2.92;3;25
TCGA-90-7769;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;MX;T2;N1;stage II;55;MALE;Alive;11.76;NA;18;DiseaseFree;11.76;3;36
TCGA-90-7964;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;squamous-like c4;MX;T2;N0;stage I;70;MALE;Alive;14.06;NA;100;DiseaseFree;14.06;4;180
TCGA-90-A4ED;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;69;MALE;Alive;20.2;NA;244;DiseaseFree;20.2;3;30
TCGA-90-A4EE;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N1;stage II;53;MALE;Alive;22.6;NA;331;DiseaseFree;22.6;2;68
TCGA-90-A59Q;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N1;stage II;61;FEMALE;Dead;10.58;NA;269;Recurred/Progressed;9;2;80
TCGA-91-6828;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;70;MALE;Alive;10.61;NA;38;DiseaseFree;10.61;3;NA
TCGA-91-6829;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;78;MALE;Dead;41.33;1258;NA;NA;NA;4;94.5
TCGA-91-6830;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;MX;T1;N1;stage II;65;FEMALE;Alive;1.97;NA;1;Recurred/Progressed;0.59;4;12
TCGA-91-6831;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;66;MALE;Alive;10.18;NA;39;DiseaseFree;10.18;2;NA
TCGA-91-6835;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;81;FEMALE;Alive;2.6;NA;35;DiseaseFree;2.6;3;25
TCGA-91-6836;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;52;FEMALE;Alive;13.7;NA;11;DiseaseFree;13.7;2;50
TCGA-91-6840;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Magnoid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;M0;T1;N0;stage I;59;FEMALE;Alive;12.22;NA;0;DiseaseFree;12.22;3;50
TCGA-91-6847;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Squamoid;NA;C1-LUAD-enriched;Cluster 6;RNA cluster 14;MX;T2;N0;stage I;62;FEMALE;Alive;27.66;NA;842;Recurred/Progressed;25.36;3;NA
TCGA-91-6848;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C12-small-various;BRCA CIMP c7;RNA cluster 2;MX;T2;N2;stage III;59;MALE;Alive;7.36;NA;127;DiseaseFree;7.36;4;NA
TCGA-91-6849;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N2;stage III;75;FEMALE;Alive;1.15;NA;35;DiseaseFree;1.15;3;30
TCGA-91-7771;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T3;N0;stage II;62;MALE;Alive;16.16;NA;31;DiseaseFree;16.16;4;75
TCGA-91-8496;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;;;MX;T2;NX;stage I;63;FEMALE;Alive;16.59;NA;197;DiseaseFree;16.59;1;NA
TCGA-91-8497;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;75;FEMALE;Dead;14.26;NA;174;NA;NA;1;NA
TCGA-91-8499;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;76;FEMALE;Alive;1.18;NA;36;DiseaseFree;1.18;2;90
TCGA-91-A4BC;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;59;MALE;Alive;1.45;NA;44;DiseaseFree;1.45;4;30
TCGA-91-A4BD;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N1;stage II;78;MALE;Alive;19.81;NA;218;DiseaseFree;19.81;3;NA
TCGA-92-7340;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;BRCA CIMP c7;squamous-like c4;MX;T2;N1;stage II;45;FEMALE;Alive;2.69;NA;82;DiseaseFree;2.69;4;15
TCGA-92-7341;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);squamous-like c4;MX;T2;N0;stage I;71;MALE;Alive;3.48;NA;106;DiseaseFree;3.48;2;50
TCGA-92-8063;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T2;N2;stage III;52;MALE;Alive;4.01;NA;122;DiseaseFree;4.01;2;74
TCGA-92-8064;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;MX;T2;N0;stage I;58;MALE;Alive;5.26;NA;160;DiseaseFree;5.26;4;30
TCGA-92-8065;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 14 (HNSC);;MX;T3;N0;stage II;74;FEMALE;Alive;2.3;NA;70;DiseaseFree;2.3;3;14
TCGA-93-7347;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Bronchioid;NA;;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;76;FEMALE;Alive;22.44;NA;297;DiseaseFree;22.44;3;11
TCGA-93-7348;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;75;FEMALE;Alive;17.44;NA;127;DiseaseFree;17.44;4;42
TCGA-93-8067;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;77;MALE;Alive;6.11;NA;186;DiseaseFree;6.11;4;20
TCGA-93-A4JN;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;M1;T2;N0;stage IV;71;MALE;Alive;23.59;NA;382;DiseaseFree;23.59;3;40
TCGA-93-A4JO;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;MX;T1;N0;stage I;70;MALE;Dead;1.08;33;NA;NA;NA;4;50
TCGA-93-A4JP;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M1;TX;NX;stage IV;64;MALE;Alive;18.99;NA;269;Recurred/Progressed;16.33;1;NA
TCGA-93-A4JQ;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;MX;T1;N0;stage I;49;MALE;Alive;17.28;NA;100;DiseaseFree;17.28;3;NA
TCGA-94-7033;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;MX;T2;N0;stage I;73;MALE;Alive;21.02;NA;87;DiseaseFree;21.02;4;30
TCGA-94-7557;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;M0;T2;N0;stage I;73;MALE;Dead;0.16;5;NA;NA;NA;2;NA
TCGA-94-7943;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 5;squamous-like c4;MX;T1;NX;stage I;80;MALE;Alive;18.36;NA;143;Recurred/Progressed;18.27;3;30
TCGA-94-8035;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;MX;T3;N0;stage II;64;MALE;Alive;4.01;NA;111;DiseaseFree;4.01;2;50
TCGA-94-8490;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);;M0;T3;N0;stage II;70;MALE;Alive;5.03;NA;153;DiseaseFree;5.03;5;NA
TCGA-94-8491;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;BRCA CIMP c7;;M0;T2;N1;stage II;73;MALE;Alive;26.61;NA;31;Recurred/Progressed;21.06;3;56
TCGA-94-A4VJ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;71;FEMALE;Alive;14.13;NA;43;DiseaseFree;14.13;4;37.5
TCGA-94-A5I4;Lung Squamous Cell Carcinoma;;;NA;;;;MX;T2;N1;stage II;61;MALE;Alive;16.13;NA;155;Recurred/Progressed;10.32;4;80
TCGA-94-A5I6;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;62;MALE;Alive;17.67;NA;185;Recurred/Progressed;15.8;4;80
TCGA-95-7039;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T3;N0;stage II;54;FEMALE;Alive;41.79;NA;34;Recurred/Progressed;41.33;2;34
TCGA-95-7043;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Magnoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;63;FEMALE;Dead;16.52;NA;2;NA;NA;4;40
TCGA-95-7562;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;71;MALE;Dead;2.86;87;NA;NA;NA;3;10
TCGA-95-7567;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N1;stage II;61;MALE;Alive;18.66;NA;163;DiseaseFree;18.66;4;NA
TCGA-95-7944;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;71;MALE;Alive;12.39;NA;21;DiseaseFree;12.39;2;50
TCGA-95-7947;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;67;MALE;Alive;15.67;NA;40;DiseaseFree;15.67;4;100
TCGA-95-7948;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;42;FEMALE;Alive;15.64;NA;133;DiseaseFree;15.64;3;0.15
TCGA-95-8039;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;72;MALE;Alive;27.27;NA;27;Recurred/Progressed;7.49;1;NA
TCGA-95-8494;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;;M0;T2;N1;stage II;67;MALE;Alive;2.76;NA;71;DiseaseFree;2.76;5;NA
TCGA-95-A4VK;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N2;stage III;74;FEMALE;Alive;21.39;NA;121;Recurred/Progressed;16.29;3;45
TCGA-95-A4VN;Lung Adenocarcinoma;Lung Solid Pattern Predominant Adenocarcinoma;;NA;;;;M0;T2;N1;stage II;62;FEMALE;Alive;18.17;NA;142;DiseaseFree;18.17;4;42
TCGA-95-A4VP;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;M0;T2;N2;stage III;66;FEMALE;Alive;19.88;NA;168;Recurred/Progressed;7.1;4;20
TCGA-96-7544;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C2-Squamous-like;Cluster 13 (HNSC-LUSC);squamous-like c4;MX;T2;N1;stage II;83;MALE;Dead;70.96;NA;1213;NA;NA;2;65
TCGA-96-7545;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 13 (HNSC-LUSC);squamous-like c4;MX;T1;N0;stage I;73;MALE;Dead;57.03;NA;1324;Recurred/Progressed;55.62;4;116
TCGA-96-8169;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;67;FEMALE;Alive;18.3;NA;189;DiseaseFree;18.3;4;35
TCGA-96-8170;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N1;stage II;75;FEMALE;Alive;17.44;NA;211;DiseaseFree;17.44;4;50
TCGA-96-A4JK;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;65;MALE;Alive;19.35;NA;273;DiseaseFree;19.35;2;110
TCGA-96-A4JL;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;78;FEMALE;Alive;27.66;NA;183;DiseaseFree;27.66;1;NA
TCGA-97-7546;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;76;FEMALE;Alive;42.21;NA;964;Recurred/Progressed;41.23;3;25
TCGA-97-7547;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;67;FEMALE;Alive;64.55;NA;1435;Recurred/Progressed;37.68;3;30
TCGA-97-7552;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Mucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T2;N0;stage I;70;MALE;Alive;63.47;NA;1476;Recurred/Progressed;26.22;3;40
TCGA-97-7553;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;C1-LUAD-enriched;Low purity c2;LUAD-like c10;MX;T1;N0;stage I;58;FEMALE;Alive;61.43;NA;1332;DiseaseFree;61.43;2;20
TCGA-97-7554;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;M0;T2;N2;stage III;83;FEMALE;Alive;25.46;NA;264;DiseaseFree;25.46;3;30
TCGA-97-7937;Lung Adenocarcinoma;Lung Micropapillary Adenocarcinoma;Squamoid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T2;N0;stage I;65;MALE;Alive;18.53;NA;181;DiseaseFree;18.53;3;35
TCGA-97-7938;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;MX;T1;N0;stage I;76;FEMALE;Dead;0.59;18;NA;NA;NA;3;40
TCGA-97-7941;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;Bronchioid;NA;C1-LUAD-enriched;Cluster 6;LUAD-like c10;MX;T1;N0;stage I;72;FEMALE;Alive;15.9;NA;22;DiseaseFree;15.9;3;22.5
TCGA-97-8171;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;LUAD-like c10;M1;T2;N2;stage IV;81;MALE;Alive;18.66;NA;107;Recurred/Progressed;14.49;2;65
TCGA-97-8172;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;75;FEMALE;Alive;17.9;NA;182;DiseaseFree;17.9;3;20
TCGA-97-8174;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;Cluster 5;LUAD-like c10;M0;T2;N0;stage II;67;MALE;Dead;5.39;164;NA;NA;NA;3;40
TCGA-97-8175;Lung Adenocarcinoma;Lung Solid Pattern Predominant Adenocarcinoma;;NA;;Cluster 6;LUAD-like c10;M0;T2;N0;stage I;55;FEMALE;Alive;18.1;NA;87;Recurred/Progressed;9.66;3;NA
TCGA-97-8176;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;;;M0;T3;N1;stage III;63;MALE;Dead;15.37;NA;252;Recurred/Progressed;1.28;4;40
TCGA-97-8177;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;59;FEMALE;Alive;16.39;NA;147;DiseaseFree;16.39;1;NA
TCGA-97-8179;Lung Adenocarcinoma;Lung Acinar Adenocarcinoma;;NA;;Cluster 6;LUAD-like c10;M0;T1;N0;stage I;72;MALE;Alive;14.29;NA;15;DiseaseFree;14.29;3;60
TCGA-97-8547;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;MX;T2;N2;stage III;78;FEMALE;Alive;21.58;NA;148;DiseaseFree;21.58;1;NA
TCGA-97-8552;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;;NA;;;;MX;T1;N0;stage I;55;FEMALE;Alive;20.57;NA;115;DiseaseFree;20.57;1;NA
TCGA-97-A4LX;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N0;stage I;81;MALE;Alive;20.17;NA;272;DiseaseFree;20.17;3;120
TCGA-97-A4M0;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T2;N0;stage I;60;FEMALE;Alive;21.42;NA;216;DiseaseFree;21.42;4;34
TCGA-97-A4M1;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;52;FEMALE;Alive;19.74;NA;209;DiseaseFree;19.74;3;3
TCGA-97-A4M2;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;66;MALE;Alive;20.5;NA;197;DiseaseFree;20.5;2;100
TCGA-97-A4M3;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;69;FEMALE;Alive;17.74;NA;237;Recurred/Progressed;1.77;3;37.5
TCGA-97-A4M5;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;83;MALE;Alive;20.83;NA;132;DiseaseFree;20.83;3;6
TCGA-97-A4M6;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;45;FEMALE;Alive;18.66;NA;185;DiseaseFree;18.66;1;NA
TCGA-97-A4M7;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;74;MALE;Alive;20.66;NA;271;DiseaseFree;20.66;3;40
TCGA-98-7454;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T2;N0;stage I;73;MALE;Alive;21.42;NA;115;DiseaseFree;21.42;3;60
TCGA-98-8020;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 14 (HNSC);;M0;T2;N2;stage III;56;FEMALE;Dead;2.76;84;NA;Recurred/Progressed;0.36;1;NA
TCGA-98-8021;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;75;FEMALE;Alive;30.78;NA;413;Recurred/Progressed;30.16;4;60
TCGA-98-8022;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T1;N0;stage I;61;MALE;Dead;30.65;NA;224;NA;NA;4;117
TCGA-98-8023;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;;M0;T3;N1;stage III;70;MALE;Alive;21.32;NA;308;DiseaseFree;21.32;2;75
TCGA-98-A538;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;67;MALE;Alive;27.14;NA;120;DiseaseFree;27.14;4;35
TCGA-98-A539;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;63;MALE;Alive;5.68;NA;118;Recurred/Progressed;5.68;2;75
TCGA-98-A53A;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;70;MALE;Dead;18.13;NA;274;NA;NA;2;80
TCGA-98-A53B;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;69;MALE;Dead;2;61;NA;NA;NA;2;40
TCGA-98-A53C;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;77;FEMALE;Alive;27;NA;311;DiseaseFree;27;4;112.5
TCGA-98-A53D;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;68;MALE;Dead;21.19;NA;22;Recurred/Progressed;13.57;4;90
TCGA-98-A53H;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;76;FEMALE;Alive;20.3;NA;169;Recurred/Progressed;14.03;2;40
TCGA-98-A53I;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;64;MALE;Alive;18.56;NA;99;DiseaseFree;18.56;4;70
TCGA-98-A53J;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;77;MALE;Alive;20.7;NA;159;DiseaseFree;20.7;3;100
TCGA-99-7458;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Nonmucinous;Bronchioid;NA;C1-LUAD-enriched;Cluster 5;LUAD-like c10;M0;T4;N0;stage III;74;FEMALE;Alive;24.54;NA;251;DiseaseFree;24.54;4;52
TCGA-99-8025;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 6;LUAD-like c10;M0;T3;N2;stage III;72;FEMALE;Alive;34.82;NA;427;DiseaseFree;34.82;4;20
TCGA-99-8028;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;50;FEMALE;Alive;36.73;NA;459;DiseaseFree;36.73;4;30
TCGA-99-8032;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M0;T1;N0;stage I;61;MALE;Alive;1.45;NA;44;DiseaseFree;1.45;2;90
TCGA-99-8033;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;M1;TX;NX;stage IV;74;FEMALE;Dead;21.55;NA;170;NA;NA;1;NA
TCGA-99-AA5R;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;70;FEMALE;Alive;21.62;NA;189;DiseaseFree;21.62;2;46
TCGA-J1-A4AH;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;70;MALE;Alive;19.09;NA;222;DiseaseFree;19.09;4;100
TCGA-J2-8192;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;Cluster 5;LUAD-like c10;MX;T2;N1;stage II;65;FEMALE;Alive;24.28;NA;154;Recurred/Progressed;15.83;1;NA
TCGA-J2-8194;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;Cluster 5;LUAD-like c10;MX;T3;N0;stage II;69;FEMALE;Alive;23.78;NA;114;Recurred/Progressed;15.44;3;20
TCGA-J2-A4AD;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;61;FEMALE;Dead;18.07;NA;287;Recurred/Progressed;17.21;2;120
TCGA-J2-A4AE;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;77;FEMALE;Alive;35.45;NA;282;DiseaseFree;35.45;1;NA
TCGA-J2-A4AG;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;66;FEMALE;Alive;32.46;NA;238;DiseaseFree;32.46;3;25
TCGA-L3-A4E7;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;71;MALE;Alive;12.88;NA;35;DiseaseFree;12.88;2;25
TCGA-L3-A524;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;45;FEMALE;Dead;16.1;NA;449;NA;NA;2;25.6
TCGA-L4-A4E5;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;48;FEMALE;Alive;18.99;NA;213;DiseaseFree;18.99;4;33
TCGA-L4-A4E6;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;67;MALE;Alive;14.29;NA;76;DiseaseFree;14.29;3;30
TCGA-L9-A443;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;63;FEMALE;Dead;6.34;NA;116;NA;NA;4;90
TCGA-L9-A444;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;60;FEMALE;Alive;10.09;NA;6;DiseaseFree;10.09;2;10
TCGA-L9-A50W;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;MX;T1;N1;stage II;75;MALE;Dead;14.52;NA;266;Recurred/Progressed;12.78;3;19
TCGA-L9-A5IP;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M1;T3;N2;stage IV;40;FEMALE;Dead;1.91;58;NA;Recurred/Progressed;1.61;4;NA
TCGA-L9-A743;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;56;MALE;Alive;21.81;NA;312;DiseaseFree;21.81;2;40.5
TCGA-L9-A7SV;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;69;MALE;Alive;18.56;NA;111;DiseaseFree;18.56;3;93
TCGA-L9-A8F4;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;64;FEMALE;Alive;15.64;NA;102;DiseaseFree;15.64;2;14
TCGA-LA-A446;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;68;MALE;Alive;13.17;NA;36;DiseaseFree;13.17;2;26
TCGA-LA-A7SW;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N1;stage III;71;MALE;Dead;13.4;NA;146;Recurred/Progressed;10.22;4;37
TCGA-MF-A522;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;54;MALE;Dead;11.83;NA;83;Recurred/Progressed;5.68;4;45
TCGA-MN-A4N1;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;60;MALE;Alive;27.17;NA;285;DiseaseFree;27.17;2;NA
TCGA-MN-A4N4;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;57;MALE;Alive;38.6;NA;622;DiseaseFree;38.6;2;NA
TCGA-MN-A4N5;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;63;MALE;Alive;2.76;NA;84;DiseaseFree;2.76;4;NA
TCGA-MP-A4SV;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;67;MALE;Dead;86.07;2620;NA;NA;NA;2;110
TCGA-MP-A4SW;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;53;MALE;Dead;58.41;1778;NA;NA;NA;3;15
TCGA-MP-A4SY;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;61;MALE;Dead;49.31;1501;NA;Recurred/Progressed;16.06;4;40
TCGA-MP-A4T2;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;71;MALE;Dead;37.32;1136;NA;Recurred/Progressed;36.47;4;75
TCGA-MP-A4T4;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;68;FEMALE;Dead;85.97;2617;NA;NA;NA;2;50
TCGA-MP-A4T6;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N2;stage III;76;FEMALE;Dead;58.8;1790;NA;NA;NA;3;50
TCGA-MP-A4T7;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M1;T2;N0;stage IV;75;FEMALE;Dead;5.49;167;NA;NA;NA;4;50
TCGA-MP-A4T8;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N2;stage III;68;MALE;Dead;5.29;161;NA;NA;NA;3;25
TCGA-MP-A4T9;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N2;stage III;54;FEMALE;Dead;41.56;1265;NA;Recurred/Progressed;41;4;24
TCGA-MP-A4TA;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;75;FEMALE;Dead;31.21;950;NA;Recurred/Progressed;23.82;4;55
TCGA-MP-A4TC;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N2;stage III;77;MALE;Dead;2.43;74;NA;NA;NA;3;125
TCGA-MP-A4TD;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N2;stage III;71;MALE;Dead;10.09;307;NA;Recurred/Progressed;7.42;3;20
TCGA-MP-A4TE;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;56;MALE;Dead;29.43;896;NA;Recurred/Progressed;27.76;4;40
TCGA-MP-A4TF;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;58;FEMALE;Dead;11.04;336;NA;Recurred/Progressed;6.41;4;40
TCGA-MP-A4TH;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;70;FEMALE;Alive;24.34;NA;142;DiseaseFree;24.34;3;20
TCGA-MP-A4TI;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;72;MALE;Dead;14.09;429;NA;Recurred/Progressed;2.76;3;35
TCGA-MP-A4TJ;Lung Adenocarcinoma;Lung Signet Ring Adenocarcinoma;;NA;;;;M0;T1;N0;stage I;62;FEMALE;Dead;11.14;339;NA;NA;NA;2;NA
TCGA-MP-A4TK;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N1;stage II;56;FEMALE;Dead;19.12;582;NA;Recurred/Progressed;17.9;4;28
TCGA-MP-A5C7;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;76;FEMALE;Alive;73.85;NA;1490;DiseaseFree;73.85;3;15
TCGA-NC-A5HD;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;79;MALE;Dead;0.07;2;NA;NA;NA;4;50
TCGA-NC-A5HE;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;60;MALE;Alive;76.74;NA;1722;DiseaseFree;76.74;4;30
TCGA-NC-A5HF;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T4;N0;stage III;74;MALE;Dead;4.53;138;NA;Recurred/Progressed;4.34;2;NA
TCGA-NC-A5HG;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T2;N2;stage III;59;MALE;Alive;64.49;NA;1548;DiseaseFree;64.49;4;80
TCGA-NC-A5HH;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T1;N0;stage I;53;MALE;Alive;1.22;NA;37;DiseaseFree;1.22;2;60
TCGA-NC-A5HI;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;68;FEMALE;Alive;57.26;NA;1135;Recurred/Progressed;2.3;2;60
TCGA-NC-A5HJ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;59;MALE;Dead;13.73;418;NA;Recurred/Progressed;10.78;4;78
TCGA-NC-A5HK;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N0;stage II;58;FEMALE;Alive;4.2;NA;128;DiseaseFree;4.2;4;40
TCGA-NC-A5HL;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage II;73;MALE;Dead;2.89;88;NA;NA;NA;4;40
TCGA-NC-A5HM;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;76;MALE;Alive;39.82;NA;29;DiseaseFree;39.82;3;50
TCGA-NC-A5HN;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N1;stage II;77;MALE;Alive;49.24;NA;894;DiseaseFree;49.24;4;100
TCGA-NC-A5HO;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N1;stage III;70;FEMALE;Alive;43.89;NA;789;DiseaseFree;43.89;4;30
TCGA-NC-A5HP;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M1;T2;N0;stage IV;69;MALE;Dead;25.3;NA;730;Recurred/Progressed;20.76;2;50
TCGA-NC-A5HQ;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N2;stage III;70;MALE;Dead;14.72;448;NA;NA;NA;2;NA
TCGA-NC-A5HR;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T2;N1;stage II;75;FEMALE;Alive;40.87;NA;623;DiseaseFree;40.87;4;35
TCGA-NC-A5HT;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T3;N1;stage III;69;MALE;Alive;26.41;NA;419;Recurred/Progressed;18.66;4;50
TCGA-NJ-A4YF;Lung Adenocarcinoma;Lung Adenocarcinoma Mixed Subtype;;NA;;;;M0;T1;N0;stage I;50;FEMALE;Alive;70.99;NA;1720;DiseaseFree;70.99;3;30
TCGA-NJ-A4YG;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;65;MALE;Alive;74.28;NA;1726;DiseaseFree;74.28;4;104
TCGA-NJ-A4YI;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M0;T2;N2;stage III;87;FEMALE;Dead;0.13;4;NA;NA;NA;3;3
TCGA-NJ-A4YP;Lung Adenocarcinoma;Lung Papillary Adenocarcinoma;;NA;;;;M0;T2;N0;stage I;52;MALE;Alive;1.64;NA;50;DiseaseFree;1.64;5;60
TCGA-NJ-A4YQ;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;69;FEMALE;Alive;47.04;NA;886;DiseaseFree;47.04;4;40
TCGA-NJ-A55A;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T2;N0;stage I;76;FEMALE;Alive;0.49;NA;3;DiseaseFree;0.49;3;25
TCGA-NJ-A55O;Lung Adenocarcinoma;Mucinous (Colloid) Carcinoma;;NA;;;;M0;T1;N1;stage II;56;FEMALE;Alive;0.43;NA;13;DiseaseFree;0.43;4;30
TCGA-NJ-A55R;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T1;N0;stage I;67;MALE;Alive;19.81;NA;603;DiseaseFree;19.81;3;5
TCGA-NJ-A7XG;Lung Adenocarcinoma;Lung Adenocarcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T4;N1;stage III;49;MALE;Alive;20.27;NA;295;DiseaseFree;20.27;3;NA
TCGA-NK-A5CR;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;77;MALE;Alive;83.51;NA;2178;DiseaseFree;83.51;3;40
TCGA-NK-A5CT;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;70;MALE;Alive;65.6;NA;1761;Recurred/Progressed;65.37;NA;80
TCGA-NK-A5CX;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage II;73;MALE;Alive;3.65;NA;111;DiseaseFree;3.65;4;40
TCGA-NK-A5D1;Lung Squamous Cell Carcinoma;Lung Basaloid Squamous Cell Carcinoma;;NA;;;;M0;T2;N1;stage II;57;MALE;Alive;16.79;NA;511;Recurred/Progressed;5.22;NA;90
TCGA-NK-A7XE;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T4;N2;stage III;66;MALE;Alive;0.43;NA;13;DiseaseFree;0.43;5;80
TCGA-O1-A52J;Lung Adenocarcinoma;;;NA;;;;MX;T1;N0;stage I;74;FEMALE;Dead;59.07;1798;NA;Recurred/Progressed;29.5;3;45
TCGA-O2-A52N;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;78;MALE;Dead;33.05;1006;NA;NA;NA;4;4.125
TCGA-O2-A52Q;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N1;stage III;44;FEMALE;Dead;3.71;113;NA;Recurred/Progressed;2.86;2;1
TCGA-O2-A52S;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T4;N2;stage III;57;FEMALE;Dead;12.71;387;NA;Recurred/Progressed;8.08;4;3
TCGA-O2-A52V;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N0;stage II;75;FEMALE;Dead;43.86;1335;NA;Recurred/Progressed;22.67;4;1
TCGA-O2-A52W;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T2;N0;stage I;63;MALE;Dead;8.57;261;NA;NA;NA;4;2.5
TCGA-O2-A5IB;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;MX;T3;N1;stage III;71;FEMALE;Dead;11.17;340;NA;Recurred/Progressed;8.31;4;2.5
TCGA-S2-AA1A;Lung Adenocarcinoma;Lung Bronchioloalveolar Carcinoma Mucinous;;NA;;;;M0;T1;N0;stage I;68;FEMALE;Alive;16.85;NA;121;DiseaseFree;16.85;3;95
TCGA-XC-AA0X;Lung Squamous Cell Carcinoma;Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS);;NA;;;;M0;T1;N0;stage I;77;FEMALE;Dead;0.2;6;NA;NA;NA;2;30
